

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the  
IPC reform  
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 13 JAN 30 Saved answer limit increased  
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA  
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 16 FEB 22 Status of current WO (PCT) information on STN  
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality  
NEWS 21 FEB 28 TOXCENTER reloaded with enhancements  
NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral  
property data  
NEWS 23 MAR 01 INSPEC reloaded and enhanced  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

10530810.trn

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:59:36 ON 02 MAR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:59:43 ON 02 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
 \*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*  
 \*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10530810\Struc 2.str

10530810.trn



```

chain nodes :
6 7 10
ring nodes :
1 2 3 4 5 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
2-11 3-7 5-6 6-10 6-12
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17
18-19 19-20 20-21 21-22
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-6 6-10 6-12
exact bonds :
2-11 3-7
normalized bonds :
11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17 18-19 19-20 20-21 21-22

```

G1:Cb,Cy,Hy

G2:H,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 10:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom

```


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10530810.trn



G1 Cb,Cy,Hy

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 08:59:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 38 TO ITERATE

100.0% PROCESSED 38 ITERATIONS 22 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 391 TO 1129  
PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 09:00:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 779 TO ITERATE

100.0% PROCESSED 779 ITERATIONS 501 ANSWERS  
SEARCH TIME: 00.00.01

L3 501 SEA SSS FUL L1

=> file medline caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'MEDLINE' ENTERED AT 09:00:14 ON 02 MAR 2006

FILE 'CAPLUS' ENTERED AT 09:00:14 ON 02 MAR 2006

10530810.trn



USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> l3

L4 23 L3

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 23 DUP REM L4 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-23

L5 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:29378 CAPLUS

DOCUMENT NUMBER: 144:121796

TITLE: Imidazole derivatives and other compounds as angiogenesis inhibitors, and their therapeutic use

INVENTOR(S): Liu, Jun; Chong, Curtis; Sullivan, David

PATENT ASSIGNEE(S): The Johns Hopkins University, USA

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004795	A2	20060112	WO 2005-US23015	20050627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-583076P P 20040625

AB Methods are disclosed for inhibiting angiogenesis and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound (e.g. an imidazole derivative) is administered to a subject.


IT 267645-83-0, BMS-337197

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imidazole derivs. and other compds. as angiogenesis inhibitors, and therapeutic use)


RN 267645-83-0 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1292132 CAPLUS  
 DOCUMENT NUMBER: 144:36330  
 TITLE: Preparation of oxazolobenzoisothiazole dioxides for prevention and treatment of diabetes  
 INVENTOR(S): Petry, Stefan; Tennagels, Norbert; Kirsch, Reinhard; Baringhaus, Karl-Heinz  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116003	A2	20051208	WO 2005-EP5321	20050514
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			DE 2004-102004026532A 20040529	
GI				



AB Title compds. I [X = O, CR<sub>2</sub>; Y = O, CR<sub>2</sub>; R<sub>1</sub>, R<sub>2</sub> = H, Aryl, CO<sub>2</sub>H, etc.; R<sub>3</sub> = H, alkyl, CO-Aryl, etc.; R<sub>4</sub>, R<sub>5</sub> = H, halo, alkyl, etc.; R<sub>6</sub>, R<sub>7</sub> = H, halo, alkyl, etc.; R<sub>8</sub> = H, CH<sub>3</sub>, CF<sub>3</sub>, etc.] and their pharmaceutically acceptable salts were prepared. For example, cyclocondensation of azide II and isothiocyanate III afforded benzoisothiazole IV in 64% yield. In protein phosphotyrosine phosphatase 1B (PTP1B) inhibition assays, 9-examples of compds. I exhibited IC<sub>50</sub> values ranging from 2.16-290  $\mu$ M.


IT 870789-56-3P 870789-57-4P 870789-58-5P  
870789-59-6P 870789-60-9P 870789-62-1P  
870789-63-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolobenzoisothiazole dioxides for prevention and treatment of diabetes)

RN 870789-56-3 CAPLUS


CN Benzonitrile, 3-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-5-yl)amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 870789-57-4 CAPLUS


CN 2,1-Benzisothiazol-5-amine, N-[5-(3-bromophenyl)-2-oxazolyl]-1,3-dihydro-,

2,2-dioxide (9CI) (CA INDEX NAME)




RN 870789-58-5 CAPLUS

CN 2,1-Benzisothiazol-5-amine, 1,3-dihydro-N-[5-(4-(trifluoromethyl)phenyl)-2-oxazolyl]-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 870789-59-6 CAPLUS

CN Phenol, 4-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-5-yl)amino]-5-oxazolyl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 870789-60-9 CAPLUS

CN 2,1-Benzisothiazol-5-amine, N-[5-(4'-chloro[1,1'-biphenyl]-4-yl)-2-oxazolyl]-1,3-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 870789-62-1 CAPLUS

CN Benzoic acid, 5-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-5-yl)amino]-5-oxazolyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 870789-63-2 CAPLUS

CN Acetic acid, [4-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-5-yl)amino]-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:395287 CAPLUS

DOCUMENT NUMBER: 142:447205

TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3

10530810.trn

INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David;  
Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco;  
Giethlen, Bruno

PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche  
Scientifique CNRS; Institut Curie

SOURCE: PCT Int. Appl., 70 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040139	A2	20050506	WO 2004-IB3698	20041022
WO 2005040139	A3	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-513214P P 20031023

OTHER SOURCE(S): MARPAT 142:447205

GI



AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further

elaborated to

give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC50 values of less than 1  $\mu$ M. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.

IT 851317-71-0P 851317-85-6P 851318-01-9P


851318-14-4P 851318-18-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)


RN 851317-71-0 CAPLUS

CN 1,3-Benzenediamine, 4-methyl-N1-(5-phenyl-2-oxazolyl)-N3-[5-(4-pyridinyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 851317-85-6 CAPLUS

CN Urea, N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 851318-01-9 CAPLUS

CN Benzamide, N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 851318-14-4 CAPLUS

CN Benzeneacetamide, 2,4-difluoro-N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 851318-18-8 CAPLUS

CN Benzeneacetamide, N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:55033 CAPLUS

DOCUMENT NUMBER: 142:155956

TITLE: Heterocyclic compounds, including [3-(4H-1,2,4-triazol-3-yl)pyridin-2-yl]amines and analogs, and their preparations, pharmaceutical compositions, and use as anticancer agents

INVENTOR(S): Ouyang, Xiaohu; Kiselyov, Alexander; Chen, Xiaoling; He, Hai-Ying; Kawakami, Joel; Pattaropong, Vatee; Piatnitski, Evgueni; Tuma, Maria Carolina; Kincaid, John

PATENT ASSIGNEE(S): Imclone Systems Incorporated, USA

SOURCE: PCT Int. Appl., 205 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

10530810.trn



## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004818	A2	20050120	WO 2004-US22226	20040709
WO 2005004818	A3	20050506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2003-485963P	P 20030709
OTHER SOURCE(S):	MARPAT 142:155956			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to heterocyclic compds. that have anticancer activity, pharmaceutical compns. that contain such compds., methods of treating diseases and conditions in mammals using the compds. and compns. and methods for their manufacture. In particular, the invention concerns compds. I and their pharmaceutically acceptable salts, stereoisomers, hydrates, and prodrugs [wherein: U/V/T = N/N/N, N/N/O, or C(R5)/N/O; X = N, CH; Z = O, S, NO<sub>2</sub>, NR<sub>4</sub>; R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub> = H, OH, halo, NO<sub>2</sub>, cyano, alk(en/yn)yl, alkoxy, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), aryloxy, (un)substituted NH<sub>2</sub>, SO<sub>2</sub>H or derivs.; R<sub>1</sub>R<sub>2</sub> may form a ring; R<sub>3</sub> = H, alk(en/yn)yl, alkoxy, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), carbonyl, SO<sub>2</sub>H or derivs., CO<sub>2</sub>H or derivs., SH or derivs., S(O)H or derivs.; R<sub>4</sub> = H, alk(en/yn)yl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), carbonyl, SO<sub>2</sub>H or derivs., S(O)H or derivs.; or R<sub>3</sub>R<sub>4</sub> forms a heterocyclic ring; R<sub>6</sub> = alk(en/yn)yl, alkoxy, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), (un)substituted NH<sub>2</sub>]. Approx. 260 compds. were prepared and biol. tested. Bioassays included an in vitro tubulin polymerization assay, a cell cycle anal., and a colorimetric (sulforhodamine B) cytotoxicity assay. For instance, invention compound II was prepared in 7 steps: (1) conversion of 2-chloropyridine-3-carboxylic acid to the Et ester, (2) aminolysis of the chloride with 3,5-dimethoxyaniline, (3) conversion of the ester to the hydrazide, (4,5) sep. preparation of N-(3,5-dimethoxyphenyl)thiourea, (6) S-methylation of the latter, and (7) cyclocondensation of the above hydrazide with the resultant isothiurea derivative to give II. The similarly prepared compound

III gave complete inhibition of bovine tubulin polymerization in vitro at 10  $\mu$ M, and gave 50% inhibition of tumor cell growth at 0.3  $\mu$ M in the sulforhodamine B assay.


IT 830333-82-9P 830333-83-0P 830333-84-1P  
 830333-85-2P 830333-86-3P 830333-87-4P  
 830333-88-5P 830333-89-6P 830333-90-9P  
 830333-91-0P 830333-93-2P 830333-95-4P  
 830333-97-6P 830333-99-8P 830334-01-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazolylpyridinylamines and analogs as tubulin polymerization inhibitors for use as anticancer agents)


RN 830333-82-9 CAPLUS

CN 2-Oxazolamine, 5-[2-[(1,3-benzodioxol-5-ylmethyl)amino]phenyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 830333-83-0 CAPLUS

CN 2-Oxazolamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[2-[[2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 830333-84-1 CAPLUS

CN 2-Oxazolamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[2-[[3,5-dimethoxyphenyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 830333-85-2 CAPLUS

CN 2-Oxazolamine, 5-[2-[[3,4-difluorophenyl)methyl]amino]phenyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 830333-86-3 CAPLUS

CN 3-Pyridinemethanamine, N-[2-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 830333-87-4 CAPLUS

CN 2-Oxazoline, 5-[2-[(1,3-benzodioxol-5-ylmethyl)amino]phenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 830333-88-5 CAPLUS

CN 2-Oxazoline, 5-[2-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]phenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 830333-89-6 CAPLUS

CN 2-Oxazoline, 5-[2-[(3,5-dimethoxyphenyl)methyl]amino]phenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 830333-90-9 CAPLUS

CN 2-Oxazoline, 5-[2-[(3,4-dimethoxyphenyl)methyl]amino]phenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 830333-91-0 CAPLUS


CN 2-Oxazoline, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[2-(4-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 830333-93-2 CAPLUS


10530810.trn

CN 2-Oxazolamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[2-(3-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 830333-95-4 CAPLUS

CN 2-Oxazolamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[2-(2-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 830333-97-6 CAPLUS

CN 2-Oxazolamine, N-(3-methoxyphenyl)-5-[2-(4-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 830333-99-8 CAPLUS

CN 2-Oxazolamine, N-(3-methoxyphenyl)-5-[2-(3-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 830334-01-5 CAPLUS

CN 2-Oxazoline, N-(3-methoxyphenyl)-5-[2-(3-methoxypropoxy)phenyl]- (9CI)  
(CA INDEX NAME)



IT 830334-40-2P 830334-41-3P 830334-42-4P


830334-43-5P 830334-44-6P 830334-45-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(intermediate; preparation of triazolypyridinylamines and analogs as  
tubulin polymerization inhibitors for use as anticancer agents)


RN 830334-40-2 CAPLUS

CN 2-Oxazoline, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-nitrophenyl)-  
(9CI) (CA INDEX NAME)




RN 830334-41-3 CAPLUS

CN 2-Oxazoline, 5-(2-aminophenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-  
(9CI) (CA INDEX NAME)




RN 830334-42-4 CAPLUS

CN 2-Oxazoline, N-(3-methoxyphenyl)-5-(2-nitrophenyl)- (9CI) (CA INDEX  
NAME)




RN 830334-43-5 CAPLUS

CN 2-Oxazolamine, 5-(2-aminophenyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 830334-44-6 CAPLUS

CN Phenol, 2-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 830334-45-7 CAPLUS

CN Phenol, 2-[2-[(3-methoxyphenyl)amino]-5-oxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L5 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1103347 CAPLUS  
 DOCUMENT NUMBER: 143:387019  
 TITLE: Preparation of thiazole tyrosine kinase inhibitors  
 INVENTOR(S): Bilodeau, Mark T.; Rodman, Leonard  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 30 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005228031	A1	20051013	US 2004-823156	20040413
PRIORITY APPLN. INFO.:			US 2004-823156	20040413
OTHER SOURCE(S):	MARPAT 143:387019			

GI



AB The title compds. I [A = (hetero)aryl; X = S, O; R1 = (un)substituted Ph, CN, (un)substituted amido; R2 = H, CN, halo, etc.; t = 0-3] which inhibit, regulate and/or modulate tyrosine kinase signal transduction, and are useful for treating tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals, were prepared. Thus, reacting (1-bromo-2,2-dimethoxyethyl)benzene with Ph thiourea afforded N,5-diphenyl-1,3-thiazol-2-amine. The compds. I inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.001-5.0  $\mu$ M. The pharmaceutical compositions comprising the compds. I alone or in combination with other therapeutic agents, are disclosed.

10530810.trn



IT 135307-33-4P 681002-66-4P 866756-95-8P


866756-96-9P 866756-97-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole tyrosine kinase inhibitors)


RN 135307-33-4 CAPLUS

CN 2-Oxazolamine, N,5-diphenyl- (9CI) (CA INDEX NAME)




RN 681002-66-4 CAPLUS

CN 2-Oxazolamine, N-(3,5-dimethoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 866756-95-8 CAPLUS

CN 2-Oxazolamine, N-(3,5-dimethylphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 866756-96-9 CAPLUS

CN 2-Oxazolamine, N-(2,3-dihydro-1H-inden-5-yl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 866756-97-0 CAPLUS

CN 2-Oxazolamine, N-[3,5-bis(trifluoromethyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:127896 CAPLUS

DOCUMENT NUMBER: 142:348122

TITLE: Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors

AUTHOR(S): Harris, Philip A.; Cheung, Mui; Hunter, Robert N., III; Brown, Matthew L.; Veal, James M.; Nolte, Robert T.; Wang, Liping; Liu, Wendy; Crosby, Renae M.; Johnson, Jennifer H.; Epperly, Andrea H.; Kumar, Rakesh; Luttrell, Deirdre K.; Stafford, Jeffrey A.

CORPORATE SOURCE: GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48(5), 1610-1619

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of derivs. of 2-anilino-5-phenyloxazole (5) has been identified as inhibitors of VEGFR2 kinase. Herein the authors describe the structure-activity relationship (SAR) of this novel template. Optimization of both aryl rings led to very potent inhibitors at both the enzymic and cellular levels. Oxazole 39 had excellent solubility and good oral PK when dosed as the bis-mesylate salt and demonstrated moderate in vivo efficacy against HT29 human colon tumor xenografts. X-ray crystallog. confirmed the proposed binding mode, and comparison of oxazoles 39 and 46 revealed interesting differences in orientation of 2-pyridyl and 3-pyridyl rings, resp., attached at the meta position of the 5-Ph ring.

IT 848902-21-6P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(2-anilino-5-aryloxazoles as a class of VEGFR2 kinase inhibitors)


RN 848902-21-6 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 681003-66-7


CMF C23 H21 N3 O4 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




IT 681003-66-7P 848902-16-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(2-anilino-5-aryloxazoles as a class of VEGFR2 kinase inhibitors)


RN 681003-66-7 CAPLUS

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 848902-16-9 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-methoxy-3-[[5-[3-(3-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




IT 135307-33-4P 681002-42-6P 681002-45-9P  
 681002-57-3P 681002-67-5P 681003-21-4P  
 681003-22-5P 681003-23-6P 681003-26-9P  
 681003-28-1P 681003-60-1P 681003-61-2P  
 681003-62-3P 681003-64-5P 681003-65-6P  
 681003-67-8P 681003-68-9P 681003-88-3P  
 681004-10-4P 681004-11-5P 848902-07-8P  
 848902-08-9P 848902-09-0P 848902-10-3P  
 848902-11-4P 848902-13-6P 848902-14-7P  
 848902-15-8P 861390-35-4P 861390-48-9P  
 861390-62-7P 861390-63-8P 861390-65-0P  
 861390-66-1P 861390-82-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(2-anilino-5-aryloxazoles as a class of VEGFR2 kinase inhibitors)


RN 135307-33-4 CAPLUS

CN 2-Oxazolamine, N,5-diphenyl- (9CI) (CA INDEX NAME)




RN 681002-42-6 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-methoxy-3-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-45-9 CAPLUS


CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-57-3 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-methoxyphenyl)-  
 (9CI) (CA INDEX NAME)



RN 681002-67-5 CAPLUS  
 CN 2-Oxazoline, N-(3-methylphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 681003-21-4 CAPLUS  
 CN 2-Oxazoline, 5-(4-chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
 (9CI) (CA INDEX NAME)




RN 681003-22-5 CAPLUS

CN Benzonitrile, 4-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-(9CI) (CA INDEX NAME)




RN 681003-23-6 CAPLUS

CN Benzamide, 4-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-(9CI) (CA INDEX NAME)




RN 681003-26-9 CAPLUS

CN 2-Oxazolamine, 5-(3-chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
(9CI) (CA INDEX NAME)



RN 681003-28-1 CAPLUS


CN Benzonitrile, 3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-  
(9CI) (CA INDEX NAME)



10530810.trn


RN 681003-60-1 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-61-2 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 681003-62-3 CAPLUS


CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-64-5 CAPLUS

CN 2-Oxazoline, 5-(3-ethylphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)







RN 681003-65-6 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(4-ethylphenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 681003-67-8 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-68-9 CAPLUS  
 CN 2-Oxazoline, 5-[1,1'-biphenyl]-3-yl-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-88-3 CAPLUS

CN Ethanone, 1-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681004-10-4 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2'-fluoro[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 681004-11-5 CAPLUS

CN 2-Oxazoline, 5-(2'-chloro[1,1'-biphenyl]-3-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 848902-07-8 CAPLUS  
 CN Benzonitrile, 2-[(5-phenyl-2-oxazolyl)amino]-, monohydrochloride (9CI)  
 (CA INDEX NAME)




● HCl

RN 848902-08-9 CAPLUS  
 CN Benzonitrile, 3-[(5-phenyl-2-oxazolyl)amino]-, monohydrochloride (9CI)  
 (CA INDEX NAME)




● HCl

RN 848902-09-0 CAPLUS  
 CN 2-Oxazamine, N-(3-phenoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 848902-10-3 CAPLUS

CN 2-Oxazolamine, N-[3-(ethylsulfonyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 848902-11-4 CAPLUS

CN Benzenesulfonamide, 4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 848902-13-6 CAPLUS

CN 2-Oxazolamine, N-(4-phenoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 848902-14-7 CAPLUS

CN 2-Oxazolamine, 5-(2-chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 848902-15-8 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 861390-35-4 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-fluorophenyl)-, ethanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 681003-30-5


CMF C18 H17 F N2 O4 S



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 861390-48-9 CAPLUS


CN 2-Oxazolamine, N-(2-methoxyphenyl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 861390-62-7 CAPLUS


CN Benzenemethanol, 3-[(5-phenyl-2-oxazolyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 861390-63-8 CAPLUS


CN 2-Oxazolamine, N-(3,4-dimethoxyphenyl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 861390-65-0 CAPLUS


CN 2-Oxazamine, N-(3,5-dimethoxyphenyl)-5-phenyl-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 861390-66-1 CAPLUS


CN 2-Oxazamine, 5-phenyl-N-(3,4,5-trimethoxyphenyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)



● HCl


RN 861390-82-1 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 681002-89-1 681003-63-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (2-anilino-5-aryloxazoles as a class of VEGFR2 kinase inhibitors)  
 RN 681002-89-1 CAPLUS  
 CN 2-Oxazamine, 5-(3-bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
 (9CI) (CA INDEX NAME)



RN 681003-63-4 CAPLUS  
 CN 2-Oxazamine, 5-(3-bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
 (9CI) (CA INDEX NAME)






IT 681003-44-1P 681003-90-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(2-anilino-5-aryloxazoles as a class of VEGFR2 kinase inhibitors)


RN 681003-44-1 CAPLUS

CN Benzenesulfonyl fluoride, 3-[[5-(3-bromophenyl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)



RN 681003-90-7 CAPLUS

CN Benzenesulfonyl fluoride, 4-methoxy-3-[[5-[3-(3-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

24


THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10530810.trn

L5 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:331949 CAPLUS  
 DOCUMENT NUMBER: 140:339318  
 TITLE: Preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors  
 INVENTOR(S): Brown, Matthew Lee; Cheung, Mui; Dickerson, Scott Howard; Gauthier, Cassandra; Harris, Philip Anthony; Hunter, Robert Neil, III; Pacofsky, Gregory; Peel, Michael Robert; Stafford, Jeffrey Alan  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 213 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032882	A2	20040422	WO 2003-US33317	20031010
WO 2004032882	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1551813 A2 20050713 EP 2003-781357 20031010 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK JP 2006503081 T2 20060126 JP 2004-543799 20031010 US 2005288515 A1 20051229 US 2005-530810 20050408 PRIORITY APPLN. INFO.: US 2002-417548P P 20021010 WO 2003-US33317 W 20031010 OTHER SOURCE(S): MARPAT 140:339318 GI				




AB The title compds. [I; D1 = (un)substituted aryl, heteroaryl, heterocyclyl; D2 = H, alkyl; D3 = (un)substituted aryl, heteroaryl] which are useful as VEGFR2, CDK2, and CDK4 inhibitors in the treatment of hyperproliferative diseases, were prepared E.g., a 5-step synthesis of I [D1 = 3-MeOC6H4; D2 = H; D3 = Ph], starting from 2-bromo-1-(3-methoxyphenyl)ethanone, was given. Different compds. I are particularly effective at inhibiting CDK2 and/or


10530810.trn

CDK4 enzymes at 0.0001 to 1  $\mu$ M and addnl. show specificity relative to other kinases. The specific data for representative compds. I are given. The pharmaceutical compns. comprising the compound I are claimed.

IT 681001-91-2P, 5-(3-Methoxyphenyl)-N-phenyl-1,3-oxazol-2-amine  
 681001-94-5P, 5-(3-Methoxyphenyl)-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-89-1P, 5-(3-Bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine  
 681003-22-5P, 4-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)benzonitrile 681003-24-7P, 5-(4-Bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-28-1P, 3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)benzonitrile 681003-45-2P, 3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl benzoate 681003-46-3P, 3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenol 681003-56-5P, 5-[3-[(2-Chloropyrimidin-4-yl)oxy]phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-88-3P, 1-[3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl]ethanone 681003-91-8P, 4-Methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonyl fluoride 681004-06-8P, Methyl 3'-(2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carboxylate 681004-31-9P, 3'-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carboxylic acid  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors for treating cancer)  
 RN 681001-91-2 CAPLUS  
 CN 2-Oxazolamine, 5-(3-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 681001-94-5 CAPLUS  
 CN 2-Oxazolamine, 5-(3-methoxyphenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-89-1 CAPLUS

CN 2-Oxazoline, 5-(3-bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
(9CI) (CA INDEX NAME)




RN 681003-22-5 CAPLUS

CN Benzonitrile, 4-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-  
(9CI) (CA INDEX NAME)




RN 681003-24-7 CAPLUS


CN 2-Oxazoline, 5-(4-bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
(9CI) (CA INDEX NAME)



RN 681003-28-1 CAPLUS  
 CN Benzonitrile, 3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-  
 (9CI) (CA INDEX NAME)




RN 681003-45-2 CAPLUS  
 CN Phenol, 3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-,  
 benzoate (ester) (9CI) (CA INDEX NAME)




RN 681003-46-3 CAPLUS

CN Phenol, 3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]- (9CI)  
(CA INDEX NAME)




RN 681003-56-5 CAPLUS

CN 2-Oxazoline, 5-[3-[(2-chloro-4-pyrimidinyl)oxy]phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 681003-88-3 CAPLUS


CN Ethanone, 1-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 681003-91-8 CAPLUS


CN Benzenesulfonyl fluoride, 4-methoxy-3-[[5-[3-(2-pyridinyl)phenyl]-2-

oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-06-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 681004-31-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)



IT 135307-33-4P 681001-92-3P, 3-(2-(Phenylamino)-1,3-oxazol-5-yl)phenol 681001-93-4P, N-[4-(4-Methylpiperazin-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine 681001-95-6P, 5-(3-Ethoxyphenyl)-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681001-96-7P, N-[4-(4-Ethylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681001-97-8P, N-[4-(4-Ethylpiperazin-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine 681001-98-9P, N-[4-(Morpholin-4-ylmethyl)phenyl]-5-phenyl-1,3-oxazol-2-amine 681001-99-0P, 5-(3-Methoxyphenyl)-N-(4-(morpholin-4-yl)phenyl)-1,3-oxazol-2-amine 681002-00-6P, 5-(3-Methoxyphenyl)-N-(4-(piperidin-1-yl)phenyl)-1,3-oxazole-2-amine 681002-01-7P, 5-(3-Methoxyphenyl)-N-(4-(morpholin-4-

yl)methyl)phenyl]-1,3-oxazole-2-amine 681002-02-8P,  
 5-(3-Isopropoxyphenyl)-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-03-9P, 5-[3-(Cyclopentyloxy)phenyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-04-0P,  
 5-(3-Isobutoxyphenyl)-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-05-1P, 5-[3-(Benzyloxy)phenyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-06-2P,  
 N-[4-(4-Methylpiperazin-1-yl)phenyl]-5-[3-[(2-methylprop-2-enyl)oxy]phenyl]-1,3-oxazol-2-amine 681002-07-3P,  
 N-[4-(4-Methylpiperazin-1-yl)phenyl]-5-(3-propoxyphenyl)-1,3-oxazol-2-amine 681002-08-4P, 5-[3-(Cyclohexyloxy)phenyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-09-5P,  
 N-[3-Chloro-4-(4-methylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-10-8P, N-[3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-11-9P,  
 5-(3-Methoxyphenyl)-N-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine 681002-12-0P,  
 5-(3-Methoxyphenyl)-N-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-13-1P, N-[4-(3,5-Dimethylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-14-2P,  
 5-(3-Methoxyphenyl)-N-[2-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-15-3P, 5-[3-(Cyclopentyloxy)phenyl]-N-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine 681002-16-4P, N-[3-Chloro-4-(4-methylpiperazin-1-yl)phenyl]-5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-amine 681002-17-5P,  
 5-[3-(Cyclopentyloxy)phenyl]-N-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-18-6P, 5-[3-(Cyclopentyloxy)phenyl]-N-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine 681002-19-7P, 3-(2-[[4-(4-Methylpiperazin-1-yl)phenyl]amino]-1,3-oxazol-5-yl)phenol 681002-20-0P 681002-28-8P,  
 5-(3-Methoxyphenyl)-N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,3-oxazol-2-amine 681002-29-9P, N-[4-[(4-Methylpiperazin-1-yl)methyl]phenyl]-5-phenyl-1,3-oxazol-2-amine 681002-30-2P,  
 N-[4-[(Dimethylamino)methyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-31-3P, 5-[3-(Cyclopentyloxy)phenyl]-N-[4-[(dimethylamino)methyl]phenyl]-1,3-oxazol-2-amine 681002-32-4P,  
 N-[4-[2-(Dimethylamino)ethyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-33-5P, 5-(3-Methoxyphenyl)-N-[4-[(piperidin-1-yl)methyl]phenyl]-1,3-oxazol-2-amine 681002-34-6P,  
 5-(3-Methoxyphenyl)-N-[4-[(pyrrolidin-1-yl)methyl]phenyl]-1,3-oxazol-2-amine 681002-35-7P, N-[4-[(Diethylamino)methyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-36-8P,  
 N-[2-(Diethylamino)ethyl]-4-[[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]amino]benzamide 681002-37-9P, 5-(3-Methoxyphenyl)-N-[4-[(4-methylpiperazin-1-yl)carbonyl]phenyl]-1,3-oxazol-2-amine 681002-38-0P, 4-[[5-[3-(Cyclopentyloxy)phenyl]-1,3-oxazol-2-yl]amino]-N-[2-(diethylamino)ethyl]benzamide 681002-40-4P,  
 N-Methyl-1-[4-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]methanesulfonamide 681002-41-5P, N-[4-[(Methylsulfonyl)methyl]phenyl]-5-phenyl-1,3-oxazol-2-amine 681002-42-6P, N,N-Diethyl-4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide 681002-43-7P,  
 N-Butyl-4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide 681002-44-8P, N-(3,4-Dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine 681002-45-9P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-phenyl-1,3-oxazol-2-amine 681002-46-0P, 5-Phenyl-N-[3-(phenylsulfonyl)phenyl]-1,3-oxazol-2-amine 681002-47-1P,  
 N,N-Diethyl-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzamide 681002-48-2P, 4-(Ethylsulfonyl)-2-[(5-phenyl-1,3-oxazol-2-yl)amino]phenol 681002-49-3P, N-(2-Methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine 681002-50-6P, N-Butyl-3-[(5-phenyl-1,3-oxazol-2-



yl)amino]benzenesulfonamide 681002-51-7P,  
N,N-Dimethyl-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide  
681002-52-8P, 2,5-Dimethoxy-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide 681002-53-9P, N-(2-Methoxy-5-nitrophenyl)-5-phenyl-1,3-oxazol-2-amine 681002-54-0P,  
2-[4-[(5-Phenyl-1,3-oxazol-2-yl)amino]phenyl]ethanol 681002-55-1P,  
1-[4-Methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]ethanone  
681002-56-2P, [3-[(5-Phenyl-1,3-oxazol-2-yl)amino]phenyl]methanol  
681002-57-3P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-58-4P,  
4-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenol  
681002-59-5P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N,N-dimethylbenzenesulfonamide 681002-60-8P,  
N-[5-(Ethylsulfonyl)-2-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine 681002-61-9P,  
N-[5-(Ethylsulfonyl)-2-[2-(pyridin-2-yl)ethoxy]phenyl]-5-phenyl-1,3-oxazol-2-amine 681002-62-0P, N-[5-(Ethylsulfonyl)-2-[2-(1H-1,2,3-triazol-1-yl)ethoxy]phenyl]-5-phenyl-1,3-oxazol-2-amine  
681002-63-1P, 5-Phenyl-N-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine 681002-64-2P, N-(2,5-Dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine 681002-65-3P, 3-Methyl-5-[(5-phenyl-1,3-oxazol-2-yl)amino]benzene-1,2-diol 681002-66-4P, N-(3,5-Dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine 681002-67-5P, N-(3-Methylphenyl)-5-phenyl-1,3-oxazol-2-amine 681002-68-6P, N-[3-[2-(1H-Imidazol-1-yl)ethoxy]-4-methoxyphenyl]-5-phenyl-1,3-oxazol-2-amine  
681002-69-7P, N-[4-[2-(1H-Imidazol-1-yl)ethoxy]-3-methoxyphenyl]-5-phenyl-1,3-oxazol-2-amine 681002-70-0P, N-[5-(Ethylsulfonyl)-2-(trifluoromethoxy)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine  
681002-71-1P, 5-(4-Fluorophenyl)-N-[2-methoxy-5-[(methylsulfonyl)methyl]phenyl]-1,3-oxazol-2-amine 681002-72-2P,  
N-(5-[[5-(3-Iodophenyl)-1,3-oxazol-2-yl]amino]-2-methylphenyl)methanesulfonamide 681002-73-3P,  
3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-N,N-dimethylbenzenesulfonamide 681002-74-4P, N-[3-(Ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine  
681002-75-5P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(pyridin-2-ylmethyl)benzenesulfonamide 681002-76-6P,  
5-(4-Fluorophenyl)-N-[2-methoxy-5-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine 681002-77-7P, N-[2-Methoxy-5-[(2-(pyridin-2-yl)ethyl)sulfonyl]phenyl]-5-phenyl-1,3-oxazol-2-amine 681002-78-8P,  
3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonamide 681002-79-9P, N-[5-[(1-Ethylpropyl)sulfonyl]-2-methoxyphenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine  
681002-80-2P, 5-(4-Fluorophenyl)-N-(2-methoxy-5-[[5-methylisoxazol-3-yl)methyl]sulfonyl]phenyl)-1,3-oxazol-2-amine  
681002-81-3P, 3-[[5-(3-Bromophenyl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonamide 681002-82-4P, 5-(4-Fluorophenyl)-N-[5-(isobutylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine  
681002-83-5P, 5-(4-Fluorophenyl)-N-[2-methoxy-5-[[tetrahydrofuran-2-yl)methyl]sulfonyl]phenyl]-1,3-oxazol-2-amine 681002-84-6P,  
5-(4-Fluorophenyl)-N-[2-methoxy-5-[(tetrahydrofuran-3-yl)sulfonyl]phenyl]-1,3-oxazol-2-amine 681002-85-7P, 5-(4-Fluorophenyl)-N-[2-methoxy-5-[[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl]phenyl]-1,3-oxazol-2-amine  
681002-86-8P, 5-(4-Fluorophenyl)-N-[5(isopropylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681002-87-9P,  
5-(3-Bromophenyl)-N-[5-(isopropylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681002-88-0P, 5-(4-Fluorophenyl)-N-[5-[[2-(1H-imidazol-2-yl)ethyl]sulfonyl]-2-methoxyphenyl]-1,3-oxazol-2-amine  
681002-90-4P, 5-(3-Bromophenyl)-N-[2-methoxy-5-[[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl]phenyl]-1,3-oxazol-2-amine

681002-91-5P, N-(2-Ethoxyphenyl)-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-92-6P, N-(3,4-Dimethoxyphenyl)-5-(3-methoxyphenyl)-1,3-oxazol-2-amine 681002-93-7P, N-(3,4-Dimethoxyphenyl)-5-(4-fluorophenyl)-1,3-oxazol-2-amine 681002-94-8P, N-(3,4-Dimethoxyphenyl)-5-(4-methylphenyl)-1,3-oxazol-2-amine 681002-95-9P, 5-(3,4-Dichlorophenyl)-N-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine 681002-96-0P, 5-[4-(Diethylamino)phenyl]-N-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine 681002-97-1P, 5-(4-Chloro-3-methylphenyl)-N-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine 681002-98-2P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine 681002-99-3P, 5-(3,4-Difluorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-00-9P, 4-Chloro-3-[[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino]-N,N-dimethylbenzenesulfonamide 681003-01-0P, 4-Chloro-N,N-diethyl-3-[[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681003-02-1P, 5-(4-Fluorophenyl)-N-[3-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine 681003-03-2P, N-[2-Chloro-5-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine 681003-04-3P, N-[2-Chloro-5-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine 681003-05-4P, 5-(4-Fluorophenyl)-N-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine 681003-06-5P, 5-(3-Bromophenyl)-N-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine 681003-07-6P, 4-Methoxy-N-(2-(morpholin-4-yl)ethyl)-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide 681003-08-7P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(3-(pyrrolidin-1-yl)propyl)benzenesulfonamide 681003-09-8P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-N-[3-(1H-imidazol-1-yl)propyl]-4-methoxybenzenesulfonamide 681003-10-1P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(pyridin-3-ylmethyl)benzenesulfonamide 681003-11-2P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(pyridin-4-ylmethyl)benzenesulfonamide 681003-12-3P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-N-isopropyl-4-methoxybenzenesulfonamide 681003-13-4P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide 681003-14-5P, 5-(4-Fluorophenyl)-N-[2-methoxy-5-((morpholin-4-yl)sulfonyl)phenyl]-1,3-oxazol-2-amine 681003-15-6P, 5-(4-Fluorophenyl)-N-[2-methoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl]-1,3-oxazol-2-amine 681003-16-7P 681003-17-8P, N-(Cyclopropylmethyl)-3-[[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonamide 681003-18-9P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(3-methoxypropyl)benzenesulfonamide 681003-19-0P, 3-[[5-(4-Fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-methylbenzenesulfonamide 681003-20-3P, N-(2-Ethoxyethyl)-3-[[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonamide 681003-21-4P, 5-(4-Chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-23-6P, 4-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)benzamide 681003-26-9P, 5-(3-Chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-29-2P, 3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)benzamide 681003-30-5P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-fluorophenyl)-1,3-oxazol-2-amine 681003-31-6P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-trifluoromethylphenyl)-1,3-oxazol-2-amine 681003-32-7P, 5-(3,4-Dichlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-33-8P, 5-(4-Chloro-3-methylphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-35-0P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(2-naphthyl)-1,3-oxazol-2-amine 681003-36-1P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(5,5,8,8-tetramethyl-5,6,7,8-

tetrahydronaphthalen-2-yl)-1,3-oxazol-2-amine 681003-37-2P,  
 5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
 1,3-oxazol-2-amine 681003-38-3P, 5-(3,5-Difluorophenyl)-N-[5-  
 (ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-39-4P  
 , N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[4-(methylsulfonyl)phenyl]-1,3-  
 oxazol-2-amine 681003-40-7P, 5-(3,4-Dimethoxyphenyl)-N-[5-  
 (ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-41-8P  
 , 5-(3,4-Dihydro-2H-1,5-benzodioxepin-7-yl)-N-[5-(ethylsulfonyl)-2-  
 methoxyphenyl]-1,3-oxazol-2-amine 681003-43-0P, Methyl  
 3-[[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino]-4-methoxybenzoate  
 681003-44-1P, 3-[[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino]-4-  
 methoxybenzenesulfonyl fluoride 681003-47-4P,  
 5-[3-(Cyclopropylmethoxy)phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-  
 oxazol-2-amine 681003-48-5P, 5-(3-Butoxyphenyl)-N-[5-  
 (ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-49-6P  
 , N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(pyridin-2-ylmethoxy)phenyl]-  
 1,3-oxazol-2-amine 681003-50-9P, 5-(3-Benzoyloxyphenyl)-N-[5-  
 (ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-51-0P  
 , N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(tetrahydro-2H-pyran-4-  
 yloxy)phenyl]-1,3-oxazol-2-amine 681003-52-1P,  
 N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-(pyridin-2-yl)ethoxy)phenyl]-  
 1,3-oxazol-2-amine 681003-53-2P, 5-[3-[(2,3-  
 Dimethoxybenzyl)oxy]phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-  
 oxazol-2-amine 681003-54-3P, N-[5-(Ethylsulfonyl)-2-  
 methoxyphenyl]-5-[3-(1-(pyridin-4-yl)ethoxy)phenyl]-1,3-oxazol-2-amine  
 681003-55-4P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-  
 (tetrahydrofuran-3-yloxy)phenyl]-1,3-oxazol-2-amine 681003-57-6P  
 , 4-[3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-  
 yl)phenoxy]-N-isopropylpyrimidin-2-amine 681003-58-7P,  
 N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-phenoxyphenyl)-1,3-oxazol-2-  
 amine 681003-59-8P, 5-(3',5'-Difluoro-1,1'-biphenyl-3-yl)-N-[5-  
 (ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-60-1P  
 , N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-(thien-2-yl)phenyl)-1,3-  
 oxazol-2-amine 681003-61-2P, N-[5-(Ethylsulfonyl)-2-  
 methoxyphenyl]-5-(3-(thien-3-yl)phenyl)-1,3-oxazol-2-amine  
 681003-62-3P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-(pyridin-  
 3-yl)phenyl)-1,3-oxazol-2-amine 681003-63-4P,  
 N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-vinylphenyl)-1,3-oxazol-2-amine  
 681003-64-5P, 5-(3-Ethylphenyl)-N-[5-(ethylsulfonyl)-2-  
 methoxyphenyl]-1,3-oxazol-2-amine 681003-65-6P,  
 N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-(pyridin-4-yl)phenyl)-1,3-  
 oxazol-2-amine 681003-66-7P, N-[5-(Ethylsulfonyl)-2-  
 methoxyphenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine  
 681003-67-8P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-methyl-  
 1H-imidazol-5-yl)phenyl]-1,3-oxazol-2-amine 681003-68-9P,  
 5-(1,1'-Biphenyl-3-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-  
 amine 681003-69-0P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-  
 (2-furyl)phenyl]-1,3-oxazol-2-amine 681003-70-3P,  
 N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(pyrazin-2-yl)phenyl]-1,3-  
 oxazol-2-amine 681003-71-4P, N-[5-(Ethylsulfonyl)-2-  
 methoxyphenyl]-5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine  
 681003-72-5P, 5-[3-(2,3-Dihydrobenzofuran-5-yl)phenyl]-N-[5-  
 (ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681003-73-6P  
 , N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1,3-thiazol-2-yl)phenyl]-1,3-  
 oxazol-2-amine 681003-74-7P, 4-Methoxy-3-[[5-(3-(pyridin-3-  
 yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681003-75-8P  
 , 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-  
 methoxybenzenesulfonamide 681003-76-9P, 4-Methoxy-3-[[5-(3-(1-  
 methyl-1H-imidazol-5-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide  
 681003-77-0P, 3-[[5-(4'-Fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-

yl]amino]-4-methoxy-N-methylbenzenesulfonamide 681003-78-1P,  
 Methyl 4-methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzoate 681003-79-2P, 3-[[5-(4'-Fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonamide 681003-80-5P, N-[5-[(1-Ethylpropyl)sulfonyl]-2-methoxyphenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine 681003-81-6P, N-[5-(Isopropylsulfonyl)-2-methoxyphenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine 681003-82-7P, N-[2-Methoxy-5-(tetrahydrofuran-3-ylsulfonyl)phenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine 681003-83-8P, N-[5-(Isobutylsulfonyl)-2-methoxyphenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine 681003-84-9P, 5-(1,1'-Biphenyl-3-yl)-N-[2-methoxy-5-[(1-(pyridin-4-yl)ethyl)sulfonyl]phenyl]-1,3-oxazol-2-amine 681003-85-0P, N-[2-Methoxy-5-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine 681003-86-1P, N-[2-Methoxy-5-[[2-(4-methyl-1,3-thiazol-5-yl)ethyl)sulfonyl]phenyl]-5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-amine 681003-87-2P, 5-(1,1'-Biphenyl-3-yl)-N-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine 681003-89-4P, 1-[4-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl]ethanone 681003-90-7P, 4-Methoxy-3-[[5-(3-(pyridin-3-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonyl fluoride 681003-92-9P, 3'-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carbonitrile 681003-95-2P, 3'-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-1,1'-biphenyl-3-carboxylic acid 681003-98-5P, 3'-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-1,1'-biphenyl-3-carbonitrile 681004-01-3P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine 681004-03-5P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-(quinolin-3-yl)phenyl)-1,3-oxazol-2-amine 681004-04-6P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-(5-methylthien-2-yl)phenyl)-1,3-oxazol-2-amine 681004-05-7P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1H-indol-5-yl)phenyl]-1,3-oxazol-2-amine 681004-07-9P, 3-[[5-(3'-Fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-methylbenzenesulfonamide 681004-08-0P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonyl fluoride 681004-09-1P, 3-[[5-(3'-Fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-methoxybenzenesulfonamide 681004-10-4P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(2'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine 681004-11-5P, 5-(2'-Chloro-1,1'-biphenyl-3-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681004-12-6P, 4-Methoxy-N-methyl-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-13-7P, N-Ethyl-4-methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-14-8P, 4-Methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-15-9P, N-Isopropyl-4-methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-16-0P, N-(Cyclopropylmethyl)-4-methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-17-1P, N,N-Diethyl-4-methoxy-3-[[5-(3-(pyridin-2-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-18-2P, N-Isopropyl-4-methoxy-3-[[5-(3-(pyridin-3-yl)phenyl)-1,3-oxazol-2-yl]amino]benzenesulfonamide 681004-19-3P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-N-isopropyl-4-methoxybenzenesulfonamide 681004-20-6P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-methoxy-N,N-dimethylbenzenesulfonamide 681004-21-7P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-N-cyclopropyl-4-methoxybenzenesulfonamide 681004-22-8P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-N-butyl-4-


methoxybenzenesulfonamide 681004-23-9P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-N,N-diethyl-4-methoxybenzenesulfonamide 681004-24-0P, 3-[[5-(1,1'-Biphenyl-3-yl)-1,3-oxazol-2-yl]amino]-4-methoxy-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide 681004-25-1P, 4-[3-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-isopropylpyrimidin-2-amine 681004-26-2P, N-Benzyl-4-[3-(2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl]pyrimidin-2-amine 681004-27-3P 681004-28-4P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-phenylpyrimidin-4-yl)phenyl]-1,3-oxazol-2-amine 681004-29-5P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-isopropylpyrimidin-4-yl)phenyl]-1,3-oxazol-2-amine 681004-30-8P, 5-[3-(2-tert-Butylpyrimidin-4-yl)phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine 681004-32-0P, 3'-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-N-(2-(morpholin-4-yl)ethyl)-1,1'-biphenyl-4-carboxamide 681004-33-1P, 3'-(2-[[5-(Ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]-1,1'-biphenyl-4-carboxamide 681004-82-0P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[4-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors for treating cancer)


RN 135307-33-4 CAPLUS

CN 2-Oxazolamine, N,5-diphenyl- (9CI) (CA INDEX NAME)




RN 681001-92-3 CAPLUS

CN Phenol, 3-[2-(phenylamino)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 681001-93-4 CAPLUS


CN 2-Oxazolamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681001-95-6 CAPLUS  
CN 2-Oxazoline, 5-(3-ethoxyphenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-  
(9CI) (CA INDEX NAME)



RN 681001-96-7 CAPLUS  
CN 2-Oxazoline, N-[4-(4-ethyl-1-piperazinyl)phenyl]-5-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 681001-97-8 CAPLUS  
CN 2-Oxazoline, N-[4-(4-ethyl-1-piperazinyl)phenyl]-5-phenyl- (9CI) (CA  
INDEX NAME)




RN 681001-98-9 CAPLUS  
CN 2-Oxazoline, N-[4-(4-morpholinylmethyl)phenyl]-5-phenyl- (9CI) (CA  
INDEX NAME)

INDEX NAME)




RN 681001-99-0 CAPLUS

CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-00-6 CAPLUS

CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-01-7 CAPLUS

CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-02-8 CAPLUS

CN 2-Oxazolamine, 5-[3-(1-methylethoxy)phenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-03-9 CAPLUS

CN 2-Oxazolamine, 5-[3-(cyclopentyloxy)phenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 681002-04-0 CAPLUS


CN 2-Oxazolamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-[3-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 681002-05-1 CAPLUS


CN 2-Oxazolamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)






RN 681002-06-2 CAPLUS

CN 2-Oxazoline, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-[3-[(2-methyl-2-propenyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-07-3 CAPLUS

CN 2-Oxazoline, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-(3-propoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-08-4 CAPLUS

CN 2-Oxazoline, 5-[3-(cyclohexyloxy)phenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-09-5 CAPLUS

CN 2-Oxazoline, N-[3-chloro-4-(4-methyl-1-piperazinyl)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-10-8 CAPLUS

CN 2-Oxazoline, N-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-11-9 CAPLUS

CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-12-0 CAPLUS

CN 2-Oxazolamine, 5-(3-methoxyphenyl)-N-[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-13-1 CAPLUS

CN 2-Oxazolamine, N-[4-(3,5-dimethyl-1-piperazinyl)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-14-2 CAPLUS

CN 2-Oxazolamine, 5-(3-methoxyphenyl)-N-[2-methyl-4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-15-3 CAPLUS

CN 2-Oxazolamine, 5-[3-(cyclopentyloxy)phenyl]-N-[4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-16-4 CAPLUS

CN 2-Oxazolamine, N-[3-chloro-4-(4-methyl-1-piperazinyl)phenyl]-5-[3-(cyclopentyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-17-5 CAPLUS

CN 2-Oxazolamine, 5-[3-(cyclopentyloxy)phenyl]-N-[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-18-6 CAPLUS

CN 2-Oxazolamine, 5-[3-(cyclopentyloxy)phenyl]-N-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-19-7 CAPLUS

CN Phenol, 3-[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 681002-20-0 CAPLUS


CN 2-Oxazolamine, 5-[3-(cyclopentyloxy)phenyl]-N-[4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-28-8 CAPLUS  
CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 681002-29-9 CAPLUS  
CN 2-Oxazoline, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-30-2 CAPLUS  
CN 2-Oxazoline, N-[4-[(dimethylamino)methyl]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-31-3 CAPLUS

CN 2-Oxazoline, 5-[3-(cyclopentyloxy)phenyl]-N-[4-  
[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-32-4 CAPLUS

CN 2-Oxazoline, N-[4-[2-(dimethylamino)ethyl]phenyl]-5-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 681002-33-5 CAPLUS

CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-(1-piperidinylmethyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 681002-34-6 CAPLUS


CN 2-Oxazoline, 5-(3-methoxyphenyl)-N-[4-(1-pyrrolidinylmethyl)phenyl]-  
(9CI) (CA INDEX NAME)



RN 681002-35-7 CAPLUS  
CN 2-Oxazoline, N-[4-[(diethylamino)methyl]phenyl]-5-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 681002-36-8 CAPLUS  
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[5-(3-methoxyphenyl)-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681002-37-9 CAPLUS  
CN Piperazine, 1-[4-[[5-(3-methoxyphenyl)-2-oxazolyl]amino]benzoyl]-4-methyl-  
(9CI) (CA INDEX NAME)






RN 681002-38-0 CAPLUS

CN Benzamide, 4-[[5-[3-(cyclopentyloxy)phenyl]-2-oxazolyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 681002-40-4 CAPLUS

CN Benzenemethanesulfonamide, N-methyl-4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-41-5 CAPLUS


CN 2-Oxazolamine, N-[4-[(methylsulfonyl)methyl]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-42-6 CAPLUS  
 CN Benzenesulfonamide, N,N-diethyl-4-methoxy-3-[(5-phenyl-2-oxazolyl)amino]-  
 (9CI) (CA INDEX NAME)



RN 681002-43-7 CAPLUS  
 CN Benzenesulfonamide, N-butyl-4-methoxy-3-[(5-phenyl-2-oxazolyl)amino]-  
 (9CI) (CA INDEX NAME)




RN 681002-44-8 CAPLUS  
 CN 2-Oxazoline, N-(3,4-dimethoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-45-9 CAPLUS

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-46-0 CAPLUS

CN 2-Oxazolamine, 5-phenyl-N-[3-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681002-47-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-48-2 CAPLUS


CN Phenol, 4-(ethylsulfonyl)-2-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-49-3 CAPLUS  
CN 2-Oxazolamine, N-(2-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-50-6 CAPLUS  
CN Benzenesulfonamide, N-butyl-3-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)



RN 681002-51-7 CAPLUS  
CN Benzenesulfonamide, N,N-dimethyl-3-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-52-8 CAPLUS  
CN Benzenesulfonamide, 2,5-dimethoxy-4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-53-9 CAPLUS

CN 2-Oxazolamine, N-(2-methoxy-5-nitrophenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-54-0 CAPLUS

CN Benzeneethanol, 4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-55-1 CAPLUS

CN Ethanone, 1-[4-methoxy-3-[(5-phenyl-2-oxazolyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-56-2 CAPLUS

CN Benzenemethanol, 3-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-57-3 CAPLUS

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-58-4 CAPLUS

CN Phenol, 4-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 681002-59-5 CAPLUS


CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 681002-60-8 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 681002-61-9 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-[2-(2-pyridinyl)ethoxy]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-62-0 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-[2-(1H-1,2,3-triazol-1-yl)ethoxy]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-63-1 CAPLUS  
CN 2-Oxazolamine, 5-phenyl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 681002-64-2 CAPLUS  
CN 2-Oxazolamine, N-(2,5-dimethoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-65-3 CAPLUS  
CN 1,2-Benzenediol, 3-methyl-5-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681002-66-4 CAPLUS  
CN 2-Oxazolamine, N-(3,5-dimethoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)







RN 681002-67-5 CAPLUS  
CN 2-Oxazoline, N-(3-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-68-6 CAPLUS  
CN 2-Oxazoline, N-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 681002-69-7 CAPLUS  
CN 2-Oxazoline, N-[4-[2-(1H-imidazol-1-yl)ethoxy]-3-methoxyphenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-70-0 CAPLUS  
CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-(trifluoromethoxy)phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 681002-71-1 CAPLUS

CN 2-Oxazamine, 5-(4-fluorophenyl)-N-[2-methoxy-5-[(methylsulfonyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-72-2 CAPLUS

CN Methanesulfonamide, N-[5-[[5-(3-iodophenyl)-2-oxazolyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 681002-73-3 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-N,N-dimethyl-  
(9CI) (CA INDEX NAME)




RN 681002-74-4 CAPLUS

CN 2-Oxazamine, N-[3-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)- (9CI) (CA  
INDEX NAME)




RN 681002-75-5 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-  
(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 681002-76-6 CAPLUS

CN 2-Oxazolamine, 5-(4-fluorophenyl)-N-[2-methoxy-5-(methylsulfonyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 681002-77-7 CAPLUS

CN 2-Oxazolamine, N-[2-methoxy-5-[[2-(2-pyridinyl)ethyl]sulfonyl]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 681002-78-8 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681002-79-9 CAPLUS


CN 2-Oxazolamine, N-[5-[(1-ethylpropyl)sulfonyl]-2-methoxyphenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 681002-80-2 CAPLUS  
 CN 2-Oxazoline, 5-(4-fluorophenyl)-N-[2-methoxy-5-[[5-methyl-3-isoxazolyl)methyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 681002-81-3 CAPLUS  
 CN Benzenesulfonamide, 3-[[5-(3-bromophenyl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681002-82-4 CAPLUS  
 CN 2-Oxazoline, 5-(4-fluorophenyl)-N-[2-methoxy-5-[(2-methylpropyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-83-5 CAPLUS

CN 2-Oxazoline, 5-(4-fluorophenyl)-N-[2-methoxy-5-[(tetrahydro-2-furanyl)methyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-84-6 CAPLUS

CN 2-Oxazoline, 5-(4-fluorophenyl)-N-[2-methoxy-5-[(tetrahydro-3-furanyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-85-7 CAPLUS

CN 2-Oxazoline, 5-(4-fluorophenyl)-N-[2-methoxy-5-[[2-(4-methyl-5-thiazolyl)ethyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-86-8 CAPLUS

CN 2-Oxazamine, 5-(4-fluorophenyl)-N-[2-methoxy-5-[(1-methylethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-87-9 CAPLUS

CN 2-Oxazamine, 5-(3-bromophenyl)-N-[2-methoxy-5-[(1-methylethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681002-88-0 CAPLUS

CN 2-Oxazamine, 5-(4-fluorophenyl)-N-[5-[[2-(1H-imidazol-2-yl)ethyl]sulfonyl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681002-90-4 CAPLUS

CN 2-Oxazamine, 5-(3-bromophenyl)-N-[2-methoxy-5-[[2-(4-methyl-5-thiazolyl)ethyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 681002-91-5 CAPLUS


CN 2-Oxazamine, N-(2-ethoxyphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681002-92-6 CAPLUS

CN 2-Oxazamine, N-(3,4-dimethoxyphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)







RN 681002-93-7 CAPLUS  
 CN 2-Oxazoline, N-(3,4-dimethoxyphenyl)-5-(4-fluorophenyl)- (9CI) (CA  
 INDEX NAME)




RN 681002-94-8 CAPLUS  
 CN 2-Oxazoline, N-(3,4-dimethoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA  
 INDEX NAME)




RN 681002-95-9 CAPLUS  
 CN 2-Oxazoline, 5-(3,4-dichlorophenyl)-N-(3,4-dimethoxyphenyl)- (9CI) (CA  
 INDEX NAME)




RN 681002-96-0 CAPLUS  
 CN 2-Oxazoline, 5-[4-(diethylamino)phenyl]-N-(3,4-dimethoxyphenyl)- (9CI)  
 (CA INDEX NAME)



RN 681002-97-1 CAPLUS  
 CN 2-Oxazoline, 5-(4-chloro-3-methylphenyl)-N-(3,4-dimethoxyphenyl)- (9CI)  
 (CA INDEX NAME)




RN 681002-98-2 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)- (9CI)  
 (CA INDEX NAME)




RN 681002-99-3 CAPLUS

CN 2-Oxazamine, 5-(3,4-difluorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-00-9 CAPLUS


CN Benzenesulfonamide, 4-chloro-3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 681003-01-0 CAPLUS  
 CN Benzenesulfonamide, 4-chloro-N,N-diethyl-3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681003-02-1 CAPLUS  
 CN 2-Oxazolamine, 5-(4-fluorophenyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 681003-03-2 CAPLUS  
 CN 2-Oxazolamine, N-[2-chloro-5-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-


10530810.trn

(9CI) (CA INDEX NAME)




RN 681003-04-3 CAPLUS

CN 2-Oxazolamine, N-[2-chloro-5-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-  
(9CI) (CA INDEX NAME)



RN 681003-05-4 CAPLUS


CN 2-Oxazolamine, 5-(4-fluorophenyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA  
INDEX NAME)



RN 681003-06-5 CAPLUS


10530810.trn

CN 2-Oxazolamine, 5-(3-bromophenyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681003-07-6 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[2-(4-morpholinyl)ethyl]-3-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 681003-08-7 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 681003-09-8 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681003-10-1 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 681003-11-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 681003-12-3 CAPLUS


CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 681003-13-4 CAPLUS  
 CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-  
 [(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 681003-14-5 CAPLUS  
 CN Morpholine, 4-[[3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-  
 methoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 681003-15-6 CAPLUS  
 CN Piperazine, 1-[[3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-  
 methoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)






RN 681003-16-7 CAPLUS

CN Thiomorpholine, 4-[[3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 681003-17-8 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681003-18-9 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 681003-19-0 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 681003-20-3 CAPLUS


CN Benzenesulfonamide, N-(2-ethoxyethyl)-3-[[5-(4-fluorophenyl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)



RN 681003-21-4 CAPLUS  
 CN 2-Oxazoline, 5-(4-chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
 (9CI) (CA INDEX NAME)




RN 681003-23-6 CAPLUS  
 CN Benzamide, 4-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-  
 (9CI) (CA INDEX NAME)




RN 681003-26-9 CAPLUS

CN 2-Oxazamine, 5-(3-chlorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-  
(9CI) (CA INDEX NAME)




RN 681003-29-2 CAPLUS


CN Benzamide, 3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-  
(9CI) (CA INDEX NAME)



RN 681003-30-5 CAPLUS  
 CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-fluorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 681003-31-6 CAPLUS  
 CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-32-7 CAPLUS  
 CN 2-Oxazamine, 5-(3,4-dichlorophenyl)-N-[5-(ethylsulfonyl)-2-

methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-33-8 CAPLUS

CN 2-Oxazolamine, 5-(4-chloro-3-methylphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 681003-35-0 CAPLUS


CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 681003-36-1 CAPLUS


10530810.trn

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 681003-37-2 CAPLUS

CN 2-Oxazolamine, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-38-3 CAPLUS

CN 2-Oxazolamine, 5-(3,5-difluorophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-39-4 CAPLUS

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-40-7 CAPLUS

CN 2-Oxazoline, 5-(3,4-dimethoxyphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 681003-41-8 CAPLUS

CN 2-Oxazoline, 5-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-43-0 CAPLUS

10530810.trn




CN Benzoic acid, 3-[[5-(3-bromophenyl)-2-oxazolyl]amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 681003-44-1 CAPLUS

CN Benzenesulfonyl fluoride, 3-[[5-(3-bromophenyl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681003-47-4 CAPLUS

CN 2-Oxazolamine, 5-[3-(cyclopropylmethoxy)phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-48-5 CAPLUS

CN 2-Oxazolamine, 5-(3-butoxyphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-49-6 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-50-9 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-51-0 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-52-1 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-[2-(2-pyridinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-53-2 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-[2-(2-pyridinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-54-3 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-[2-(2-pyridinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-55-4 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-[(tetrahydro-3-furanyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-57-6 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681003-58-7 CAPLUS

CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681003-59-8 CAPLUS

CN 2-Oxazoline, 5-(3',5'-difluoro[1,1'-biphenyl]-3-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-60-1 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-61-2 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-62-3 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-63-4 CAPLUS

CN 2-Oxazoline, 5-(3-ethenylphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-64-5 CAPLUS

CN 2-Oxazoline, 5-(3-ethylphenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-65-6 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-66-7 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-67-8 CAPLUS


CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-methyl-1H-imidazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 681003-68-9 CAPLUS  
 CN 2-Oxazoline, 5-[1,1'-biphenyl]-3-yl-N-[5-(ethanesulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-69-0 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethanesulfonyl)-2-methoxyphenyl]-5-[3-(2-furanyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-70-3 CAPLUS  
 CN 2-Oxazoline, N-[5-(ethanesulfonyl)-2-methoxyphenyl]-5-(3-pyrazinylphenyl)- (9CI) (CA INDEX NAME)







RN 681003-71-4 CAPLUS  
 CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4'-fluoro[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 681003-72-5 CAPLUS  
 CN 2-Oxazamine, 5-[3-(2,3-dihydro-5-benzofuranyl)phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681003-73-6 CAPLUS  
 CN 2-Oxazamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-thiazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-74-7 CAPLUS  
 CN Benzenesulfonamide, 4-methoxy-3-[[5-[3-(3-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)



RN 681003-75-8 CAPLUS  
 CN Benzenesulfonamide, 3-[(5-[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681003-76-9 CAPLUS  
 CN Benzenesulfonamide, 4-methoxy-3-[[5-[3-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681003-77-0 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4'-fluoro[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 681003-78-1 CAPLUS

CN Benzoic acid, 4-methoxy-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 681003-79-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-(4'-fluoro[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681003-80-5 CAPLUS

CN 2-Oxazamine, N-[5-[(1-ethylpropyl)sulfonyl]-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-81-6 CAPLUS

CN 2-Oxazamine, N-[2-methoxy-5-[(1-methylethyl)sulfonyl]phenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-82-7 CAPLUS

CN 2-Oxazamine, N-[2-methoxy-5-[(tetrahydro-3-furanyl)sulfonyl]phenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-83-8 CAPLUS

CN 2-Oxazoline, N-[2-methoxy-5-[(2-methylpropyl)sulfonyl]phenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-84-9 CAPLUS

CN 2-Oxazoline, 5-[1,1'-biphenyl]-3-yl-N-[2-methoxy-5-[[1-(4-pyridinyl)ethyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-85-0 CAPLUS


CN 2-Oxazoline, N-[2-methoxy-5-[[1-(4-pyridinyl)ethyl]sulfonyl]phenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681003-86-1 CAPLUS  
 CN 2-Oxazoline, N-[2-methoxy-5-[[2-(4-methyl-5-thiazolyl)ethyl]sulfonyl]phenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 681003-87-2 CAPLUS  
 CN 2-Oxazoline, 5-[1,1'-biphenyl]-3-yl-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 681003-89-4 CAPLUS  
 CN Ethanone, 1-[4-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681003-90-7 CAPLUS

CN Benzenesulfonyl fluoride, 4-methoxy-3-[[5-[[3-(3-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681003-92-9 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 681003-95-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 681003-98-5 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 681004-01-3 CAPLUS


CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3'-fluoro[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)



RN 681004-03-5 CAPLUS


CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(3-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)






RN 681004-04-6 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(5-methyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 681004-05-7 CAPLUS

CN 2-Oxazoline, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1H-indol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 681004-07-9 CAPLUS


CN Benzenesulfonamide, 3-[[5-(3'-fluoro[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 681004-08-0 CAPLUS  
 CN Benzenesulfonyl fluoride, 3-[(5-[1,1'-biphenyl]-3-yl-2-oxazolyl)amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681004-09-1 CAPLUS  
 CN Benzenesulfonamide, 3-[[5-(3'-fluoro[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 681004-10-4 CAPLUS  
 CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2'-fluoro[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 681004-11-5 CAPLUS  
CN 2-Oxazoline, 5-(2'-chloro[1,1'-biphenyl]-3-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 681004-12-6 CAPLUS  
CN Benzenesulfonamide, 4-methoxy-N-methyl-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-13-7 CAPLUS  
CN Benzenesulfonamide, N-ethyl-4-methoxy-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-14-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-15-9 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-(1-methylethyl)-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-16-0 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-methoxy-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-17-1 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-methoxy-3-[[5-[3-(2-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-18-2 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-(1-methylethyl)-3-[[5-[3-(3-pyridinyl)phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 681004-19-3 CAPLUS

CN Benzenesulfonamide, 3-[[5-[1,1'-biphenyl]-3-yl]-2-oxazolyl]amino]-4-methoxy-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681004-20-6 CAPLUS

CN Benzenesulfonamide, 3-[(5-[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 681004-21-7 CAPLUS

CN Benzenesulfonamide, 3-[(5-[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-N-cyclopropyl-4-methoxy- (9CI) (CA INDEX NAME)




RN 681004-22-8 CAPLUS

CN Benzenesulfonamide, 3-[(5-[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-N-butyl-4-methoxy- (9CI) (CA INDEX NAME)




RN 681004-23-9 CAPLUS

CN Benzenesulfonamide, 3-[(5-[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-N,N-diethyl-4-methoxy- (9CI) (CA INDEX NAME)




RN 681004-24-0 CAPLUS

CN Benzenesulfonamide, 3-[(5-[1,1'-biphenyl]-3-yl)-2-oxazolyl]amino]-4-methoxy-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 681004-25-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681004-26-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 681004-27-3 CAPLUS


CN 1,3-Propanediamine, N'-[4-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 681004-28-4 CAPLUS


CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-phenyl-4-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)






RN 681004-29-5 CAPLUS

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-[2-(1-methylethyl)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 681004-30-8 CAPLUS

CN 2-Oxazolamine, 5-[3-[2-(1,1-dimethylethyl)-4-pyrimidinyl]phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 681004-32-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 681004-33-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3'-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 681004-82-0 CAPLUS

CN 2-Oxazolamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 681004-54-6P, (2E)-3-(Dimethylamino)-1-[3-(2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl]prop-2-en-1-one


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors for treating cancer)

RN 681004-54-6 CAPLUS

CN 2-Propen-1-one, 3-(dimethylamino)-1-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1082034 CAPLUS

DOCUMENT NUMBER: 142:56293

TITLE: P-38 inhibitors

INVENTOR(S): Dong, Qing; Pierre, Fabrice; Wang, Jianqiang

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 76 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004254236	A1	20041216	US 2004-860768	20040602
CA 2528438	AA	20050106	CA 2004-2528438	20040602
WO 2005000298	A2	20050106	WO 2004-US17580	20040602
WO 2005000298	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:



US 2003-475662P P 20030603

US 2003-531541P P 20031219

WO 2004-US17580 W 20040602

OTHER SOURCE(S): MARPAT 142:56293

GI



AB 5-Membered heterocycle-based p38 kinase inhibitors I (R1 = H, Me, halogen, OH, lower alkyl, lower cycloalkyl, lower alkynyl, CF3, OMe, OCF3, CN, NH2, alkylamine, alkoxy; R2 = alkyl, substituted alkyl, lower cycloalkyl, halo, CF3, OCF3, alkoxy, alkylamine, sulfoxy, sulfone, amide, and n = 0, 1, or 2; R3 = H, alkyl, alkoxy, substituted alkyl, cycloalkyl, heteroaryl, heterocycle; Y = a single bond, C(O)NH, NHC(O), NHC(O)NH, SO2NH, NHSO2, C(O); B = a 5-membered heterocyclic ring system optionally substituted; Q = a single bond, O, S, alkylamine, SO, SO2, C(O), CO(O), C(O)NH, CH2; D = a monocyclic or bicyclic ring system) are prepared for the treatment of inflammatory and autoimmune diseases. Thus, to 3-amino-N-methoxy-4-methylbenzamide in CH2Cl2 was added benzoyl isothiocyanate, and N, N-diisopropylethylamine followed by treatment with hydrazine monohydrate to give II. II had an IC50 of less than 50 nM against p38α.


IT 808737-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of p-38 kinase inhibitors for the treatment of inflammatory and autoimmune diseases)

RN 808737-97-5 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[(5-phenyl-2-oxazolyl)amino]- (9CI)  
(CA INDEX NAME)



L5 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:362591 CAPLUS

DOCUMENT NUMBER: 141:106407

TITLE: The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase

AUTHOR(S): Bilodeau, Mark T.; Rodman, Leonard D.; McGaughey, Georgia B.; Coll, Kathleen E.; Koester, Timothy J.; Hoffman, William F.; Hungate, Randall W.; Kendall, Richard L.; McFall, Rosemary C.; Rickert, Keith W.; Rutledge, Ruth Z.; Thomas, Kenneth A.


CORPORATE SOURCE: Departments of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),

10530810.trn

PUBLISHER:  
DOCUMENT TYPE:  
LANGUAGE:  
OTHER SOURCE(S):  
GI

14(11), 2941-2945  
CODEN: BMCLE8; ISSN: 0960-894X  
Elsevier Science B.V.  
Journal  
English  
CASREACT 141:106407




AB An azo-dye lead was modified to a N-(1,3-thiazol-2-yl)pyridin-2-amine series of KDR kinase inhibitors through the use of rapid analog libraries. The two lead compds. were N-butyl-N,3-dimethyl-4-[(5-nitro-2-thiazolyl)azo]benzenamine and N-(5-phenyl-2-thiazolyl)benzamide. This class has been found to be potent, selective, and of low mol. weight. Mol. modeling has postulated an interesting conformational preference and binding mode for these compds. in the active site of the enzyme. A binding mode was proposed for the lead compound N-(5-phenyl-2-thiazolyl)-2-pyridinamine (I) in the KDR kinase active site.

IT 135307-33-4P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of N-(thiazolyl)pyridinamines, and analogs, study of their activity as KDR kinase inhibitors, structure-activity relationship, and evaluation of diphenyloxazolamine analog)

RN 135307-33-4 CAPLUS

CN 2-Oxazolamine, N,5-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:2836 CAPLUS

DOCUMENT NUMBER: 140:77135

TITLE: Preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa.

INVENTOR(S): Slusasrchyk, William A.; Bolton, Scott A.; Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

10530810.trn

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000788	A1	20031231	WO 2003-US19605	20030617
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2003245614	A1	20040106	AU 2003-245614	20030617
US 2004019085	A1	20040129	US 2003-464035	20030617
US 6846838	B2	20050125		
EP 1551794	A1	20050713	EP 2003-739243	20030617
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
PRIORITY APPLN. INFO.:			US 2002-389832P	P 20020619
			WO 2003-US19605	W 20030617
OTHER SOURCE(S):		MARPAT 140:77135		
GI				




AB Title compds. [I; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R<sup>4</sup>, R<sup>5</sup> = H, halo, OH, cyano, alkoxy, OCF<sub>3</sub>, amino, etc.; R<sup>6</sup> = H, (substituted) alkyl; R<sup>7</sup>, R<sup>8</sup> = H, halo, OH, cyano, alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, amino, (substituted) alkyl, etc.; R<sup>9</sup>, R<sup>10</sup> = H, (substituted) alkyl; NR<sup>9</sup>R<sup>10</sup> = 3-8 membered (substituted) heterocyclyl; R<sup>11</sup> = 0-4 halo, cyano, NO<sub>2</sub>, (substituted) alkyl, alkenyl, alkynyl, etc.; R<sup>12</sup> = H, (substituted) alkyl; R<sup>13</sup>, R<sup>14</sup> = H, (substituted) alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.









REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:2622 CAPLUS

DOCUMENT NUMBER: 140:53429

TITLE: Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor VIIa-associated conditions

INVENTOR(S): Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott; Dhar, T. G. Murali

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000214	A2	20031231	WO 2003-US19155	20030617
WO 2004000214	A3	20040325		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004029940	A1	20040212	US 2003-464366	20030617
EP 1532103	A2	20050525	EP 2003-742043	20030617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-389833P	P 20020619
			WO 2003-US19155	W 20030617

OTHER SOURCE(S): MARPAT 140:53429

AB Use of at least one compound having an amine nucleus, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in the manufacture of a medicament useful for treating conditions associated with the activity of Factor VIIa is described.

IT 639458-85-8P 639458-86-9P 639458-87-0P  
639458-89-2P 639458-92-7P 639458-94-9P


639458-95-0P 639458-96-1P 639458-97-2P  
 639458-98-3P 639458-99-4P 639459-00-0P  
 639459-01-1P 639459-02-2P 639459-03-3P  
 639459-04-4P 639459-05-5P 639459-06-6P  
 639459-07-7P 639459-08-8P 639459-09-9P  
 639459-10-2P 639459-11-3P 639459-12-4P  
 639459-13-5P 639459-14-6P 639459-15-7P  
 639459-16-8P 639459-17-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of compds. for treating factor VIIa-associated conditions)


RN 639458-85-8 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639458-86-9 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-(1-naphthalenylamino)-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639458-87-0 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[(4-phenoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639458-89-2 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-(phenylmethoxy)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639458-92-7 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639458-94-9 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(2-methoxy[1,1'-biphenyl]-4-yl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639458-95-0 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639458-96-1 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639458-97-2 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(1H-tetrazol-5-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639458-98-3 CAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[4-(4-isothiazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639458-99-4 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 639459-00-0 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-(2-naphthalenylamino)-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639459-01-1 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-((2-methyl-5-benzothiazolyl)amino)-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639459-02-2 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-(1H-benzimidazol-5-ylamino)-5-

oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-03-3 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(1H-imidazol-4-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-04-4 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[2-(2-furanyl)-5-benzoxazolyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-05-5 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-chloro-4-(2-thiazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-06-6 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-ethyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-07-7 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-08-8 CAPLUS


CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(4-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 639459-09-9 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(5-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639459-10-2 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-11-3 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(1-methyl-1H-pyrazol-5-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)






RN 639459-12-4 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-13-5 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639459-14-6 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-15-7 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-(1H-indazol-5-ylamino)-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-16-8 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-[5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 639459-17-9 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



IT 639459-18-0 639459-19-1 639459-20-4


639459-21-5 639459-22-6 639459-23-7

639459-24-8 639459-25-9 639459-26-0  
 639459-27-1 639459-28-2 639459-29-3  
 639459-30-6 639459-31-7 639459-32-8  
 639459-33-9 639459-34-0 639459-35-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (use of compds. for treating factor VIIa-associated conditions)


RN 639459-18-0 CAPLUS

CN Acetamide, 2-amino-N-[[5-fluoro-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-19-1 CAPLUS

CN Acetamide, 2-amino-N-[1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-20-4 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(4-ethyl-4,5-dihydro-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-21-5 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(4,5-dihydro-4-methyl-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-22-6 CAPLUS

CN Acetamide, 2-amino-N-[[5-chloro-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-23-7 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(4-ethyl-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-24-8 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(4-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-25-9 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(3-furanyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-26-0 CAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-methyl-5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-27-1 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-28-2 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[[4-cyano-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-29-3 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[[4-bromo-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-30-6 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-methyl-1-propenyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 639459-31-7 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[[4-[(hydroxyamino)iminomethyl]-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639459-32-8 CAPLUS  
 CN Acetamide, 2-amino-N-ethyl-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 639459-33-9 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 639459-34-0 CAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[4-(2-furanyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 639459-35-1 CAPLUS

CN Cyclopentanecarboxamide, 1-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)





L5 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:746351 CAPLUS

DOCUMENT NUMBER: 139:381329

TITLE: 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships

AUTHOR(S): Dhar, T. G. Murali; Shen, Zhongqi; Gu, Henry H.; Chen, Ping; Norris, Derek; Watterson, Scott H.; Ballentine, Shelley K.; Fleener, Catherine A.; Rouleau, Katherine A.; Barrish, Joel C.; Townsend, Robert; Hollenbaugh, Diane L.; Iwanowicz, Edwin J.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(20), 3557-3560

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:381329

AB A series of novel small mol. inhibitors of inosine monophosphate dehydrogenase (IMPDH), based upon a 3-cyanoindole core, were explored. IMPDH catalyzes the rate determining step in guanine nucleotide biosynthesis and


is a target for anticancer, immunosuppressive and antiviral therapy. The synthesis and the structure-activity relationships (SAR), derived from in vitro studies, for this new series of inhibitors is given. Compds. thus prepared and screened included 1-methyl-6-[[[(phenylamino)carbonyl]amino]-1H-indole-3-carbonitrile, 1-methyl-6-[[[(2-methylphenyl)amino]carbonyl]amino]-1H-indole-3-carbonitrile, 1-methyl-6-[[[(4-methylphenyl)amino]carbonyl]amino]-1H-indole-3-carbonitrile, 6-[(5-phenyl-2-oxazolyl)amino]-1H-indole-3-carbonitrile.

IT 625116-07-6 625116-08-7 625116-09-8  
625116-10-1 625116-11-2 625116-13-4  
625116-14-5 625116-15-6 625116-16-7  
625116-17-8 625116-18-9 625116-21-4  
625116-22-5 625116-24-7 625116-25-8  
625116-26-9


RL: PAC (Pharmacological activity); BIOL (Biological study)  
(preparation and structure-activity relationships of 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase)

RN 625116-07-6 CAPLUS


CN 1H-Indole-3-carbonitrile, 1-methyl-6-[(5-phenyl-2-oxazolyl)amino]- (9CI)  
(CA INDEX NAME)




RN 625116-08-7 CAPLUS  
 CN 1H-Indole-3-carbonitrile, 1-methyl-6-[[5-(2-methylphenyl)-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)



RN 625116-09-8 CAPLUS  
 CN 1H-Indole-3-carbonitrile, 1-methyl-6-[[5-(3-methylphenyl)-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 625116-10-1 CAPLUS  
 CN 1H-Indole-3-carbonitrile, 1-methyl-6-[[5-(4-methylphenyl)-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 625116-11-2 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625116-13-4 CAPLUS

CN 1H-Indole-3-carbonitrile, 6-[[5-[3-(aminomethyl)phenyl]-2-oxazolyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 625116-14-5 CAPLUS


CN 1H-Indole-3-carbonitrile, 6-[[5-[4-(aminomethyl)phenyl]-2-oxazolyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 625116-15-6 CAPLUS  
 CN Benzamide, N-[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]-(9CI) (CA INDEX NAME)



RN 625116-16-7 CAPLUS  
 CN Benzamide, N-[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 625116-17-8 CAPLUS  
 CN Benzamide, N-[4-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 625116-18-9 CAPLUS

CN Acetamide, N-[[4-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 625116-21-4 CAPLUS

CN 1-Naphthalenecarboxamide, N-[[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 625116-22-5 CAPLUS


CN Carbamic acid, [[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)




RN 625116-24-7 CAPLUS  
 CN Carbamic acid, [[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 625116-25-8 CAPLUS  
 CN Carbamic acid, [[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)



RN 625116-26-9 CAPLUS  
 CN Carbamic acid, [[2-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)




IT 625116-12-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and structure-activity relationships of 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase)

RN 625116-12-3 CAPLUS

CN 1H-Indole-3-carbonitrile, 6-[[5-[2-(aminomethyl)phenyl]-2-oxazolyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




IT 625116-19-0P 625116-20-3P 625116-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure-activity relationships of 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase)


RN 625116-19-0 CAPLUS

CN Propanamide, N-[[4-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 625116-20-3 CAPLUS

CN 2-Naphthalenecarboxamide, N-[[3-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 625116-23-6 CAPLUS

CN Carbamic acid, [[2-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyl]phenyl]methyl]-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)



IT 625116-30-5P 625116-31-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and structure-activity relationships of 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase)


RN 625116-30-5 CAPLUS

CN 1H-Indole-3-carbonitrile, 6-[[5-[2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-2-oxazolyl]amino]-1-methyl- (9CI) (CA INDEX NAME)





RN 625116-31-6 CAPLUS  
 CN Carbamic acid, [[2-[2-[(3-cyano-1-methyl-1H-indol-6-yl)amino]-5-oxazolyloxy]phenyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:405949 CAPLUS

DOCUMENT NUMBER: 139:127427

TITLE: Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyloxy)phenyl] moiety

AUTHOR(S): Iwanowicz, Edwin J.; Watterson, Scott H.; Guo, Junqing; Pitts, William J.; Murali Dhar, T. G.; Shen, Zhongqi; Chen, Ping; Gu, Henry H.; Fleener, Catherine A.; Rouleau, Katherine A.; Cheney, Daniel L.; Townsend, Robert M.; Hollenbaugh, Diane L.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(12), 2059-2063

10530810.trn

CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 139:127427

AB The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyl)phenyl] moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described. The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogs) are given.


IT 267645-83-0P 267646-00-4P 267646-03-7P  
 267647-66-5P 267647-67-6P 267647-68-7P  
 267647-69-8P 267647-71-2P 267647-72-3P  
 267647-73-4P 267647-74-5P 437655-90-8P  
 568556-36-5P 568556-37-6P 568556-38-7P  
 568556-39-8P 568556-40-1P 568556-41-2P  
 568556-42-3P 568556-48-9P 568556-49-0P  
 568556-50-3P 568556-51-4P 568556-52-5P  
 568556-53-6P 568556-54-7P 568556-55-8P  
 568556-56-9P 568556-59-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitors of inosine monophosphate dehydrogenase and structure-activity relations about the 3-Methoxy(5-oxazolyl)phenyl moiety in relation to inhibition of T-cell proliferation)


RN 267645-83-0 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267646-00-4 CAPLUS

CN Phenol, 2-(5-oxazolyl)-5-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 267646-03-7 CAPLUS

CN 2-Oxazolamine, N-[3-ethoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 267647-66-5 CAPLUS

CN Acetamide, N-[2-[2-[[3-bromo-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-67-6 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-bromo-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-68-7 CAPLUS

CN Acetamide, N-[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-69-8 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-71-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[2-[[3-methyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267647-72-3 CAPLUS

CN 4-Morpholineacetamide, N-methyl-N-[2-[2-[[3-methyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267647-73-4 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 267647-74-5 CAPLUS

CN 2-Oxazolamine, N-[4-(4-methyl-5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 437655-90-8 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 568556-36-5 CAPLUS


CN 2-Oxazolamine, N-[4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-37-6 CAPLUS  
CN 2-Oxazolamine, N-[3-chloro-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-38-7 CAPLUS  
CN 2-Oxazolamine, N-[2-chloro-5-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 568556-39-8 CAPLUS  
CN 2-Oxazolamine, N-[2-chloro-3-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-40-1 CAPLUS  
CN 2-Oxazolamine, N-[2-chloro-5-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-41-2 CAPLUS  
CN 4-Morpholineacetamide, N-[2-[2-[[3-ethyl-4-(5-oxazolyl)phenyl]amino]-5-phenyl]-5-phenyl- (9CI) (CA INDEX NAME)

oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 568556-42-3 CAPLUS

CN Acetamide, N-[2-[2-[[3-ethyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)




RN 568556-48-9 CAPLUS

CN 2-Oxazoline, N-[3-methoxy-4-(4-methyl-5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-49-0 CAPLUS


CN 2-Oxazoline, N-[3-methoxy-4-(2-methyl-5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-50-3 CAPLUS  
CN 2-Oxazamine, N-[4-(2,4-dimethyl-5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-51-4 CAPLUS  
CN 2-Oxazamine, N-[4-(4-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 568556-52-5 CAPLUS  
CN 2-Oxazamine, N-[3-methoxy-4-(4-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 568556-53-6 CAPLUS  
CN 2-Oxazamine, N-[3-methyl-4-(4-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 568556-54-7 CAPLUS  
CN 2-Oxazamine, N-[3-chloro-4-(4-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




INDEX NAME)




RN 568556-55-8 CAPLUS

CN 4-Morpholineacetamide, N-[3-[2-[[3-methoxy-4-(4-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 568556-56-9 CAPLUS

CN Acetamide, 2-hydroxy-N-[3-[2-[[3-methoxy-4-(4-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 568556-59-2 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(2-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




IT 267645-38-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitors of inosine monophosphate dehydrogenase and structure-activity relations about the 3-Methoxy(5-oxazolyl)phenyl

moiety in relation to inhibition of T-cell proliferation)  
 RN 267645-38-5 CAPLUS  
 CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




IT 679001-60-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (inhibitors of inosine monophosphate dehydrogenase and structure-activity relations about the 3-Methoxy(5-oxazolyl)phenyl moiety in relation to inhibition of T-cell proliferation)  
 RN 679001-60-6 CAPLUS  
 CN Carbamic acid, [3-methoxy-4-(5-oxazolyl)phenyl] (5-phenyl-2-oxazolyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:236040 CAPLUS  
 DOCUMENT NUMBER: 139:133492  
 TITLE: Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors  
 AUTHOR(S): Chen, Ping; Norris, Derek; Haslow, Kristin D.; Murali Dhar, T. G.; Pitts, William J.; Watterson, Scott H.; Cheney, Daniel L.; Bassolino, Donna A.; Fleener, Catherine A.; Rouleau, Katherine A.; Hollenbaugh, Diane L.; Townsend, Robert M.; Barrish, Joel C.; Iwanowicz, Edwin J.  
 CORPORATE SOURCE: Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1345-1348  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 139:133492  
 GI




AB Screening of our inhouse compound collection led to the discovery of 5-bromo-6-aminoisoquinoline (I) as a weak inhibitor of IMPDH. Subsequent optimization of I afforded a series of novel 2-isoquinolinoaminooxazole-based inhibitors, e.g., II, with single-digit nanomolar potency against the enzyme.

IT **566944-20-5P 566944-22-7P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation, IMPDH inhibition, and structure-activity relationships of isoquinolinyl- and quinazolinylaminooxazoles via heterocyclization of corresponding isothiocyanates with azidoacetophenone)

RN 566944-20-5 CAPLUS  
 CN 6-Isoquinolinamine, N-(5-phenyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



RN 566944-22-7 CAPLUS  
 CN 7-Quinazolinamine, N-(5-phenyl-2-oxazolyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:755249 CAPLUS  
 DOCUMENT NUMBER: 137:263025  
 TITLE: Preparation of substituted oxazoles as IMPDH inhibitors  
 INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent

10530810.trn

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002143176	A1	20021003	US 2001-997963	20011129
US 6596747	B2	20030722		
US 6399773	B1	20020604	US 1999-428432	19991027
WO 2003047512	A2	20030612	WO 2002-US38038	20021127
WO 2003047512	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1448187	A2	20040825	EP 2002-789910	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 1998-106186P	P 19981029
			US 1999-428432	A2 19991027
			US 2001-997963	A 20011129
			WO 2002-US38038	W 20021127
OTHER SOURCE(S):			MARPAT 137:263025	
GI				




AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared

5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimidate (CH<sub>3</sub>CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.


- IT 267645-48-7P, 5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxazole 267647-75-6P, 2-[[3-Methoxy-4-cyanophenyl]amino]-5-phenyloxazole 463941-31-3P, 2-Amino-N-[2-[2-(3-methoxy-4-methylphenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-36-8P, 2-Amino-N-[2-[2-(3-methoxyphenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-37-9P, 2-Amino-N-methyl-N-[2-(2-phenylaminooxazol-5-yl)benzyl]acetamide 463941-38-0P, 2-Amino-N-[2-[2-(3-chlorophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-39-1P, 2-Amino-N-[2-[2-(4-chlorophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-40-4P, 2-Amino-N-[2-[2-(4-methoxyphenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-41-5P, 2-Amino-N-[2-[2-(2,4-dichlorophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-42-6P, 2-Amino-N-[2-[2-(3,4-dichlorophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-43-7P, 2-Amino-N-[2-[2-(3-cyanophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-44-8P, 2-Amino-N-[2-[2-(4-cyanophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-45-9P, 2-Amino-N-[2-[2-(4-tert-butylphenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-46-0P, 4-[[5-[2-[[2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]benzoic acid methyl ester 463941-47-1P, 2-Amino-N-methyl-N-[2-[2-(4-nitrophenylamino)oxazol-5-yl]benzyl]acetamide 463941-48-2P, N-[2-[2-(4-Acetylphenylamino)oxazol-5-yl]benzyl]-2-amino-N-methylacetamide 463941-49-3P, 2-Amino-N-methyl-N-[2-[2-(3-nitrophenylamino)oxazol-5-yl]benzyl]acetamide 463941-50-6P, 4-[[5-[2-[[2-Aminoacetyl)methyl]amino]methyl]phenyl]oxazol-2-yl]amino]benzamide 463941-51-7P, 2-Amino-N-[2-[2-(4-butyrylphenylamino)oxazol-5-yl]benzyl]-N-methylacetamide 463941-52-8P, N-[2-[2-(3-Acetylaminophenyl)amino]oxazol-5-yl]benzyl]-2-amino-N-methylacetamide 463941-53-9P, 3-[[5-[2-[[2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-N-methylbenzamide 463941-54-0P, N-[2-[2-((4-Acetylaminophenyl)amino)oxazol-5-yl]benzyl]-2-amino-N-methylacetamide 463941-55-1P, 4-[[5-[2-[[2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-2-methoxybenzoic acid methyl ester
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)
- RN 267645-48-7 CAPLUS
- CN 2-Oxazolamine, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




- RN 267647-75-6 CAPLUS
- CN Benzonitrile, 2-methoxy-4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 463941-31-3 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[(3-methoxy-4-methylphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 463941-36-8 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[(3-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-37-9 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-(phenylamino)-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 463941-38-0 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(3-chlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-39-1 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(4-chlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-40-4 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(4-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-41-5 CAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[(2,4-dichlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-42-6 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[(3,4-dichlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 463941-43-7 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[(3-cyanophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-44-8 CAPLUS  
 CN Acetamide, 2-amino-N-[[2-[2-[(4-cyanophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)






RN 463941-45-9 CAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(1,1-dimethylethyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-46-0 CAPLUS

CN Benzoic acid, 4-[[5-[2-[[3-amino-2-oxopropyl]amino]methyl]phenyl]-2-oxazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 463941-47-1 CAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-nitrophenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 463941-48-2 CAPLUS


CN Acetamide, N-[[2-[2-[[4-acetylphenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-49-3 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[(3-nitrophenyl)amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 463941-50-6 CAPLUS  
 CN Benzamide, 4-[[5-[2-[[[(3-amino-2-oxopropyl)amino]methyl]phenyl]-2-oxazolyl]amino]- (9CI) (CA INDEX NAME)




RN 463941-51-7 CAPLUS  
 CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[4-(1-oxobutyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 463941-52-8 CAPLUS  
 CN Acetamide, N-[[2-[2-[[3-(acetylamino)phenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 463941-53-9 CAPLUS  
 CN Benzamide, 3-[[5-[2-[[3-(3-amino-2-oxopropyl)amino]methyl]phenyl]-2-oxazolyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 463941-54-0 CAPLUS  
 CN Acetamide, N-[[2-[2-[[4-(acetylamino)phenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (9CI) (CA INDEX NAME)



RN 463941-55-1 CAPLUS  
 CN Benzoic acid, 4-[[5-[2-[[[(3-amino-2-oxopropyl)amino]methyl]phenyl]-2-oxazolyl]amino]-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:808839 CAPLUS  
 DOCUMENT NUMBER: 138:255135  
 TITLE: The TosMIC approach to 3-(Oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors  
 AUTHOR(S): Dhar, T. G. Murali; Shen, Zhongqi; Fleener, Catherine A.; Rouleau, Katherine A.; Barrish, Joel C.; Hollenbaugh, Diane L.; Iwanowicz, Edwin J.  
 CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(22), 3305-3308  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 138:255135  
 AB A modified approach to the synthesis of 3-(oxazolyl-5-yl) indoles is reported. This method was applied to the synthesis of series of novel indole based inhibitors of inosine monophosphate dehydrogenase (IMPDH). The synthesis and the structure-activity relationships (SARs), derived from in vitro studies, for this new series of inhibitors is given.  
 IT 502622-79-9P 502622-80-2P 502622-81-3P  
 502622-82-4P 502622-84-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of (oxazolyl)indole derivs. via tosylmethyl isocyanide reagent method and their structure-activity relationships as inosine

monophosphate dehydrogenase inhibitors)


RN 502622-79-9 CAPLUS

CN 1H-Indol-6-amine, 3-(5-oxazolyl)-N-(5-phenyl-2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 502622-80-2 CAPLUS

CN 1H-Indol-6-amine, N-[5-(2-methylphenyl)-2-oxazolyl]-3-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 502622-81-3 CAPLUS

CN 1H-Indol-6-amine, N-[5-(4-methylphenyl)-2-oxazolyl]-3-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 502622-82-4 CAPLUS


CN 1H-Indol-6-amine, N-[5-(3-methylphenyl)-2-oxazolyl]-3-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 502622-84-6 CAPLUS  
 CN 4-Morpholineacetamide, N-methyl-N-[2-[2-[[3-(5-oxazolyl)-1H-indol-6-yl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



IT 593254-70-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of (oxazolyl)indole derivs. via tosylmethyl isocyanide reagent method and their structure-activity relationships as inosine monophosphate dehydrogenase inhibitors)  
 RN 593254-70-7 CAPLUS  
 CN Acetamide, 2-hydroxy-N-methyl-N-[2-[2-[[3-(5-oxazolyl)-1H-indol-6-yl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



IT 502622-83-5P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (substitution of; preparation of (oxazolyl)indole derivs. via tosylmethyl isocyanide reagent method and their structure-activity relationships as inosine monophosphate dehydrogenase inhibitors)  
 RN 502622-83-5 CAPLUS  
 CN Acetamide, 2-(acetyloxy)-N-methyl-N-[2-[2-[[3-(5-oxazolyl)-1H-indol-6-yl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:767300 CAPLUS

DOCUMENT NUMBER: 138:378530

TITLE: A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase

AUTHOR(S): Dhar, T. G. Murali; Liu, Chunjian; Pitts, William J.; Guo, Junquing; Watterson, Scott H.; Gu, Henry; Fleener, Catherine A.; Rouleau, Katherine; Sherbina, N. Z.; Barrish, Joel C.; Hollenbaugh, Diane; Iwanowicz, Edwin J.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(21), 3125-3128  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:378530

AB A series of heterocyclic replacements for the central diamide moiety of one diamide compound, a potent small mol. inhibitor of inosine monophosphate dehydrogenase (IMPDH) were explored. The synthesis and the structure-activity relationships (SARs), derived from in vitro studies, for these new series of inhibitors is given.


IT 267645-38-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure-activity relationship of cyclic diamide derivs. as inhibitors of inosine monophosphate dehydrogenase)

RN 267645-38-5 CAPLUS


CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:294377 CAPLUS  
 DOCUMENT NUMBER: 137:41266  
 TITLE: Discovery of N-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a Novel and Potent Inhibitor of Inosine Monophosphate Dehydrogenase with Excellent in Vivo Activity  
 AUTHOR(S): Dhar, T. G. Murali; Shen, Zhongqi; Guo, Junqing; Liu, Chunjian; Watterson, Scott H.; Gu, Henry H.; Pitts, William J.; Fleener, Catherine A.; Rouleau, Katherine A.; Sherbina, N. Z.; McIntyre, Kim W.; Witmer, Mark R.; Tredup, Jeffrey A.; Chen, Bang-Chi; Zhao, Rulin; Bednarz, Mark S.; Cheney, Daniel L.; MacMaster, John F.; Miller, Laura M.; Berry, Karen K.; Harper, Timothy W.; Barrish, Joel C.; Hollenbaugh, Diane L.; Iwanowicz, Edwin J.  
 CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Inst., Princeton, NJ, 08543-4000, USA  
 SOURCE: Journal of Medicinal Chemistry (2002), 45(11), 2127-2130  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 137:41266  
 GI



I

AB Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme that is involved in the de novo synthesis of purine nucleotides. Novel 2-aminooxazoles were synthesized and tested for inhibition of IMPDH catalytic activity. Multiple analogs based on this chemotype were found to inhibit IMPDH with low nanomolar potency. One of the analogs (I) showed excellent in vivo activity in the inhibition of antibody production in mice and in the adjuvant induced arthritis model in rats.  
 IT 267645-83-0P, BMS 337197  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (2-aminooxazoles as inhibitors of inosine monophosphate dehydrogenase)  
 RN 267645-83-0 CAPLUS  
 CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)






IT 437655-91-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(2-aminooxazoles as inhibitors of inosine monophosphate dehydrogenase)

RN 437655-91-9 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 267645-38-5 267645-40-9 267645-43-2  
267645-44-3 267645-45-4 267645-46-5  
267645-47-6 267645-53-4 267645-54-5  
267645-61-4 267645-66-9 267645-70-5  
267645-71-6 267645-72-7 267645-73-8  
267645-75-0 267645-78-3 267645-79-4  
267645-84-1 267645-86-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(2-aminooxazoles as inhibitors of inosine monophosphate dehydrogenase)


RN 267645-38-5 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 267645-40-9 CAPLUS

CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-43-2 CAPLUS

CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-44-3 CAPLUS

CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-45-4 CAPLUS


CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(4-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-46-5 CAPLUS  
 CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(3-methylphenyl)-  
 (9CI) (CA INDEX NAME)



RN 267645-47-6 CAPLUS  
 CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-methylphenyl)-  
 (9CI) (CA INDEX NAME)




RN 267645-53-4 CAPLUS  
 CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 267645-54-5 CAPLUS

CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-61-4 CAPLUS

CN Benzoic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 267645-66-9 CAPLUS

CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 267645-70-5 CAPLUS


CN 4-Morpholinepropanamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-71-6 CAPLUS  
 CN Acetamide, 2-(dimethylamino)-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267645-72-7 CAPLUS  
 CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 267645-73-8 CAPLUS  
 CN 1-Piperazineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)




RN 267645-75-0 CAPLUS

CN Acetamide, 2-[(1,1-dimethylethyl)amino]-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-78-3 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-79-4 CAPLUS

CN 2H-1,2,3-Triazole-2-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-84-1 CAPLUS

CN Benzoic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267645-86-3 CAPLUS

CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-methyl- (9CI) (CA INDEX NAME)




IT 437655-88-4P 437655-90-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(2-aminooxazoles as inhibitors of inosine monophosphate dehydrogenase)


RN 437655-88-4 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 437655-90-8 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:378144 CAPLUS

DOCUMENT NUMBER: 137:109226

TITLE: A Modified Approach to 2-(N-Aryl)-1,3-oxazoles: Application to the Synthesis of the IMPDH Inhibitor BMS-337197 and Analogs

AUTHOR(S): Dhar, T. G. Murali; Guo, Junqing; Shen, Zhongqi; Pitts, William J.; Gu, Henry H.; Chen, Bang-Chi; Zhao, Rulin; Bednarz, Mark S.; Iwanowicz, Edwin J.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Organic Letters (2002), 4(12), 2091-2093

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:109226

GI





I

AB A modified approach to the synthesis of 2-(N-aryl)-1,3-oxazoles, employing an optimized iminophosphorane/heterocumulene-mediated methodol., and its application to the synthesis of BMS-337197 (I), a potent inhibitor of IMPDH, are described.


IT 437655-88-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(modified approach to 2-(arylamino)-1,3-oxazoles and its application to preparation of the IMPDH inhibitor BMS-337197 and analogs)

RN 437655-88-4 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




IT 267645-61-4P 267645-83-0P 267647-75-6P  
442849-40-3P 442849-41-4P 442849-42-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(modified approach to 2-(arylamino)-1,3-oxazoles and its application to preparation of the IMPDH inhibitor BMS-337197 and analogs)


RN 267645-61-4 CAPLUS

CN Benzoic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 267645-83-0 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-75-6 CAPLUS

CN Benzonitrile, 2-methoxy-4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)




RN 442849-40-3 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 442849-41-4 CAPLUS

CN Benzonitrile, 4-[(5-phenyl-2-oxazolyl)amino]-2-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)



RN 442849-42-5 CAPLUS

CN Benzoic acid, 2-methoxy-4-[(5-phenyl-2-oxazolyl)amino]-, methyl ester  
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:314540 CAPLUS

DOCUMENT NUMBER: 132:334477

TITLE: Preparation of compounds derived from an amine nucleus as inhibitors of IMPDH enzyme

INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William John

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 191 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025780	A1	20000511	WO 1999-US24825	19991022
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2348234	AA	20000511	CA 1999-2348234	19991022
EP 1126843	A1	20010829	EP 1999-955142	19991022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 764479	B2	20030821	AU 2000-11315	19991022
PRIORITY APPLN. INFO.:			US 1998-106186P	P 19981029
			WO 1999-US24825	W 19991022
OTHER SOURCE(S):		MARPAT 132:334477		
GI				




AB The title compds. XN(R)BD [I; X = (un)substituted monocyclic or bicyclic ring system optionally containing up to 4 heteroatoms selected from N, O, and S; R = H, alkyl; B = (un)substituted monocyclic or bicyclic ring system optionally containing up to 4 heteroatoms selected from N, O, and S; D = (un)substituted monocyclic or bicyclic ring system optionally containing up to 4 heteroatoms selected from N, O, and S], useful in treating or preventing IMPDH (inosine-5'-monophosphate dehydrogenase) mediated diseases, such as transplant rejection and autoimmune diseases, were prepared E.g., a multi-step synthesis of triazole II was given. Compds. I are effective at 0.1-500 mg/kg/day.


IT 267645-38-5P 267645-55-6P 267645-61-4P  
267646-00-4P 267647-65-4P 267647-70-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of compds. derived from an amine nucleus as inhibitors of IMPDH enzyme)

RN 267645-38-5 CAPLUS


CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 267645-55-6 CAPLUS  
CN 2-Oxazolamine, 5-(2-bromophenyl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI)  
(CA INDEX NAME)




RN 267645-61-4 CAPLUS  
CN Benzoic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 267646-00-4 CAPLUS  
CN Phenol, 2-(5-oxazolyl)-5-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)



RN 267647-65-4 CAPLUS  
CN Acetamide, 2-(acetyloxy)-N-[2-[2-[[3-bromo-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267647-70-1 CAPLUS  
 CN Acetamide, 2-(acetyloxy)-N-methyl-N-[2-[2-[[3-methyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




IT 267645-40-9P 267645-43-2P 267645-44-3P  
 267645-45-4P 267645-46-5P 267645-47-6P  
 267645-48-7P 267645-49-8P 267645-51-2P  
 267645-53-4P 267645-54-5P 267645-57-8P  
 267645-58-9P 267645-59-0P 267645-60-3P  
 267645-62-5P 267645-63-6P 267645-64-7P  
 267645-65-8P 267645-66-9P 267645-69-2P  
 267645-70-5P 267645-71-6P 267645-72-7P  
 267645-73-8P 267645-74-9P 267645-75-0P  
 267645-76-1P 267645-77-2P 267645-78-3P  
 267645-79-4P 267645-80-7P 267645-81-8P  
 267645-82-9P 267645-83-0P 267645-84-1P  
 267645-85-2P 267645-86-3P 267645-87-4P  
 267645-88-5P 267645-89-6P 267645-90-9P  
 267645-91-0P 267646-01-5P 267646-02-6P  
 267646-03-7P 267646-04-8P 267646-05-9P  
 267647-53-0P 267647-54-1P 267647-55-2P  
 267647-56-3P 267647-57-4P 267647-58-5P  
 267647-59-6P 267647-60-9P 267647-61-0P  
 267647-62-1P 267647-63-2P 267647-64-3P  
 267647-66-5P 267647-67-6P 267647-68-7P  
 267647-69-8P 267647-71-2P 267647-72-3P  
 267647-73-4P 267647-74-5P 267647-75-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of compds. derived from an amine nucleus as inhibitors of IMPDH enzyme)


RN 267645-40-9 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-43-2 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-44-3 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-45-4 CAPLUS


CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(4-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-46-5 CAPLUS  
CN 2-Oxazoline, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(3-methylphenyl)-  
(9CI) (CA INDEX NAME)



RN 267645-47-6 CAPLUS  
CN 2-Oxazoline, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 267645-48-7 CAPLUS  
CN 2-Oxazoline, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 267645-49-8 CAPLUS  
CN 2-Oxazoline, 5-[4-(diethylamino)phenyl]-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)







RN 267645-51-2 CAPLUS  
 CN 2-Oxazoline, 5-(2,6-dimethoxyphenyl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]-  
 (9CI) (CA INDEX NAME)




RN 267645-53-4 CAPLUS  
 CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267645-54-5 CAPLUS  
 CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-57-8 CAPLUS  
 CN Acetamide, 2-methoxy-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 267645-58-9 CAPLUS  
 CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267645-59-0 CAPLUS  
 CN Acetamide, 2-methoxy-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-60-3 CAPLUS

CN 2-Oxazamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 267645-62-5 CAPLUS

CN Carbamic acid, [2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)




RN 267645-63-6 CAPLUS

CN Carbamic acid, [2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)




RN 267645-64-7 CAPLUS

CN 2-Oxazolidinone, 3-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267645-65-8 CAPLUS

CN Carbamic acid, [2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 267645-66-9 CAPLUS


CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 267645-69-2 CAPLUS  
 CN 4-Morpholineacetamide, N-ethyl-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 267645-70-5 CAPLUS  
 CN 4-Morpholinepropanamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-71-6 CAPLUS  
 CN Acetamide, 2-(dimethylamino)-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-72-7 CAPLUS

CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-2-(methlamino)- (9CI) (CA INDEX NAME)




RN 267645-73-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)




RN 267645-74-9 CAPLUS

CN 1H-1,2,4-Triazole-1-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-75-0 CAPLUS

CN Acetamide, 2-[(1,1-dimethylethyl)amino]-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-76-1 CAPLUS

CN Acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-2-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 267645-77-2 CAPLUS

CN 1H-Imidazole-1-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-78-3 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267645-79-4 CAPLUS


CN 2H-1,2,3-Triazole-2-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267645-80-7 CAPLUS


CN 1H-1,2,3-Triazole-1-acetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)






RN 267645-81-8 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N,α-dimethyl- (9CI) (CA INDEX NAME)




RN 267645-82-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-83-0 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267645-84-1 CAPLUS

CN Benzoic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-(9CI) (CA INDEX NAME)




RN 267645-85-2 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 267645-86-3 CAPLUS


CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267645-87-4 CAPLUS


CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-[(3S)-tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267645-88-5 CAPLUS

CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 267645-89-6 CAPLUS

CN Piperazine, 1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 267645-90-9 CAPLUS

CN Benzamide, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 267645-91-0 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methyl-5-phenyl- (9CI)  
(CA INDEX NAME)




RN 267646-01-5 CAPLUS

CN Acetic acid, [2-(5-oxazolyl)-5-[(5-phenyl-2-oxazolyl)amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 267646-02-6 CAPLUS

CN Acetic acid, [2-(5-oxazolyl)-5-[(5-phenyl-2-oxazolyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 267646-03-7 CAPLUS

CN 2-Oxazolamine, N-[3-ethoxy-4-(5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 267646-04-8 CAPLUS

CN Acetonitrile, [2-(5-oxazolyl)-5-[(5-phenyl-2-oxazolyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 267646-05-9 CAPLUS


CN Acetic acid, [5-[[5-(2-bromophenyl)-2-oxazolyl]amino]-2-(5-oxazolyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 267647-53-0 CAPLUS  
 CN 1-Piperidineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267647-54-1 CAPLUS  
 CN 1-Piperidineacetamide, 4-hydroxy-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-55-2 CAPLUS  
 CN Acetamide, 2-(cyclohexylmethylamino)-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 267647-56-3 CAPLUS


CN 1-Piperidineacetamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 267647-57-4 CAPLUS


CN 1-Pyrrolidineacetamide, 2-(methoxymethyl)-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267647-58-5 CAPLUS

CN Acetamide, 2-amino-N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-59-6 CAPLUS

CN Propanamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 267647-60-9 CAPLUS


CN Propanamide, N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 267647-61-0 CAPLUS


CN Acetic acid, [[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methylamino]oxo-, ethyl ester (9CI) (CA INDEX NAME)






RN 267647-62-1 CAPLUS

CN Acetic acid, [[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methylamino]oxo- (9CI) (CA INDEX NAME)




RN 267647-63-2 CAPLUS

CN Benzeneacetic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 267647-64-3 CAPLUS

CN Benzeneacetamide, N-[(1-ethyl-3-pyrrolidinyl)methyl]-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 267647-66-5 CAPLUS

CN Acetamide, N-[2-[2-[[3-bromo-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-67-6 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-bromo-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-68-7 CAPLUS

CN Acetamide, N-[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-69-8 CAPLUS

CN 4-Morpholineacetamide, N-[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 267647-71-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[2-[[3-methyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267647-72-3 CAPLUS

CN 4-Morpholineacetamide, N-methyl-N-[2-[2-[[3-methyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)




RN 267647-73-4 CAPLUS

CN 2-Oxazolamine, N-[3-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 267647-74-5 CAPLUS

CN 2-Oxazolamine, N-[4-(4-methyl-5-oxazolyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 267647-75-6 CAPLUS

CN Benzonitrile, 2-methoxy-4-[(5-phenyl-2-oxazolyl)amino]- (9CI) (CA INDEX NAME)



IT 267648-00-0P 267648-01-1P 267648-02-2P


267648-03-3P 267648-05-5P 267648-06-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of compds. derived from an amine nucleus as inhibitors of IMPDH enzyme)



RN 267648-00-0 CAPLUS

CN Benzoic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 267648-01-1 CAPLUS

CN Benzoic acid, 2-[2-[[[(1,1-dimethylethoxy)carbonyl][3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 267648-02-2 CAPLUS


CN Benzoic acid, 2-[2-[[[(1,1-dimethylethoxy)carbonyl][3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 267648-03-3 CAPLUS  
 CN Carbamic acid, [3-methoxy-4-(5-oxazolyl)phenyl] [5-[2-  
 [(methylamino)carbonyl]phenyl]-2-oxazolyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)




RN 267648-05-5 CAPLUS  
 CN Carbamic acid, [3-hydroxy-4-(5-oxazolyl)phenyl] (5-phenyl-2-oxazolyl)-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 267648-06-6 CAPLUS

CN Phenol, 5-[[5-(2-bromophenyl)-2-oxazolyl]amino]-2-(5-oxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:511641 CAPLUS

DOCUMENT NUMBER: 127:135812

TITLE: Preparation of 2-phenyl-3-(aminoalkyl)indole derivatives as antagonists of gonadotropin releasing hormone (GnRH)

INVENTOR(S): Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Wyvratt, Matthew J.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Wyvratt, Matthew J.

SOURCE: PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721707	A1	19970619	WO 1996-US19767	19961210
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2240111	AA	19970619	CA 1996-2240111	19961210
AU 9712876	A1	19970703	AU 1997-12876	19961210
AU 707277	B2	19990708		
EP 882040	A1	19981209	EP 1996-943711	19961210



10530810.trn

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

CN 1209129	A	19990224	CN 1996-199923	19961210
JP 11502538	T2	19990302	JP 1996-522193	19961210
NZ 325060	A	20000228	NZ 1996-325060	19961210
JP 2000212161	A2	20000802	JP 2000-36746	19961210
JP 3092946	B2	20000925	JP 1997-522193	19961210
US 6197975	B1	20010306	US 1998-77565	19980601
NO 9802730	A	19980813	NO 1998-2730	19980612
PRIORITY APPLN. INFO.:			US 1995-8631P	P 19951214
			GB 1996-3344	A 19960216
			US 1996-760866	B1 19961205
			JP 1997-522193	A3 19961210
			WO 1996-US19767	W 19961210

OTHER SOURCE(S):                    MARPAT 127:135812

GI



AB There are disclosed compds. of formula [I; A = (un)substituted C1-6 alkyl, C3-7 cycloalkyl, C3-6 alkenyl, or C3-6 alkynyl, C1-6 alkoxy, etc.; R0 = halo, (un)substituted C1-6 alkyl; R1 = (un)substituted Ph or naphthyl; R2 = H, (un)substituted C1-6 alkyl, aralkyl, or aryl, etc.; or R2 and A taken together form a ring of 5-7 atoms; R3 - R5 = H, (un)substituted C1-6 alkyl or C2-6 alkenyl, cyano, NO2, C1-3 perfluoroalkyl, perfluoroalkoxy, (un)substituted aryl, etc.; R3 and R4 taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing 1-3 heteroatoms selected from N, O, and S; R6 = H, (un)substituted C1-6 alkyl or aryl, cyano, NO2, halo, etc.; R7 = H, (un)substituted C1-6 alkyl, unless X = H or halo, then R7 is absent; R8 = CO2R20, CONR20R21, NR20R21, COR20, NR21COR20, NR21CONR20R21, NR20SO2R21, etc.; wherein R20, R21 = H, (un)substituted C1-6 alkyl, aryl, aralkyl, a carbocyclic ring of 3-7 atoms, or a heterocyclic ring or bicyclic heterocyclic ring with 1-4 heteroatoms; R9, R9a, R10, R10a = H, (un)substituted C1-6 alkyl, aryl, or aralkyl when m ≠ 0; or e.g. R9 and R9a (when m ≠ 0) or R10 and R10a taken together form a carbocyclic ring of 3-7 atoms or O when m = 0] and pharmaceutically acceptable salts thereof. They are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women,



e.g. sex-hormone dependent cancers, benign prostatic hypertrophy or myoma of the uterus (no data). Thus, a solution of 5-hydroxyindole derivative (II);

R =

H, R0 = CO2CH2Ph, R1 = CH2Ph) in CH2Cl2 was treated at 0° with triphosgene and a solution of pyridine in CH2Cl2 and stirred for 20 min and the reaction mixture was added to morpholine in CH2CH2 at 0° and stirred at room temperature for 45 min to give the morpholine-4-carboxylic acid ester II (R = morpholine-4-carboxyloxy, R0 = CO2CH2Ph, R1 = CH2Ph). This was hydrogenolyzed in the presence of 10% Pd-C in AcOH under hydrogen

atmospheric

to give II (R = morpholine-4-carboxyloxy, R0 = R1 = H).


IT 193016-39-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenyl(aminoalkyl)indole derivs. as antagonists of gonadotropin releasing hormone for treatment of sex-hormone related conditions)

RN 193016-39-6 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[2-[2-(3,5-dimethylphenyl)-5-[(5-phenyl-2-oxazolyl)amino]-1H-indol-3-yl]ethyl]amino]butyl]phenyl]- (9CI) (CA INDEX NAME)





IT 193017-11-7P 193017-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(preparation of phenyl(aminoalkyl)indole derivs. as antagonists of gonadotropin releasing hormone for treatment of sex-hormone related conditions)

RN 193017-11-7 CAPLUS

CN Carbamic acid, [4-[4-[bis(methylsulfonyl)amino]phenyl]butyl][2-[2-(3,5-dimethylphenyl)-5-[(5-phenyl-2-oxazolyl)amino]-1H-indol-3-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 193017-12-8 CAPLUS  
 CN Carbamic acid, [2-[2-(3,5-dimethylphenyl)-5-[(5-phenyl-2-oxazolyl)amino]-1H-indol-3-yl]ethyl] [4-[4-[(methylsulfonyl)amino]phenyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1995:332256 CAPLUS  
 DOCUMENT NUMBER: 122:265286  
 TITLE: Formation of 2-alkylaminooxazoles by the Rh2(OAc)4-catalyzed reaction of  $\alpha$ -diazocarbonyl compounds in the presence of cyanamides  
 AUTHOR(S): Fukushima, Kazuaki; Ibata, Toshikazu  
 CORPORATE SOURCE: Dep. Chem., Osaka Univ., Osaka, 560, Japan  
 SOURCE: Heterocycles (1995), 40(1), 149-54  
 CODEN: HTCYAM; ISSN: 0385-5414

10530810.trn

PUBLISHER: Japan Institute of Heterocyclic Chemistry  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 122:265286  
 AB The Rh2(OAc)4-catalyzed reaction of  $\alpha$ -diazoacetophenones with N,N-dialkylcyanamides gave the corresponding 2-(N,N-dialkylamino)-5-aryloxazoles in high yields. Although para-substituents of the diazoacetophenone and the N-alkyl groups of cyanamide did not affect the yields of the oxazole, unsubstituted and monosubstituted cyanamides gave the corresponding 2-aminooxazoles in low yields. 2-(N,N-Dialkylamino)-5-alkoxyoxazoles formed by the similar reaction of diazoacetates with N,N-dialkylcyanamides were unstable upon isolation.  
 IT 162789-65-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 162789-65-3 CAPLUS  
 CN 2-Oxazoline, N-methyl-5-(4-nitrophenyl)-N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1991:471440 CAPLUS  
 DOCUMENT NUMBER: 115:71440  
 TITLE: New applications of iminophosphoranes. The preparation of  $\beta$ -keto carbodiimides and their rearrangement to 2-amino-1,3-oxazoles  
 AUTHOR(S): Froeyen, Paul  
 CORPORATE SOURCE: Dep. Chem., Agric. Univ. Norway, Aas, 1432, Norway  
 SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (1991), 60(1-2), 81-4  
 CODEN: PSSLEC; ISSN: 1042-6507  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 115:71440  
 GI



AB  $\beta$ -Keto carbodiimides RN:C:NCHR2COR1 (R = Ph, 1-naphthyl; R1 = Me, Ph, etc.; R2 = H, Me) have been synthesized by reacting 2-azido ketones


N3CHR2COR1 with triphenylphosphine in the presence of isocyanates/isothiocyanates; the former compds. are readily transformed into 2-amino-1,3-oxazoles (I; same R, R1, R2).

IT 135307-33-4P 135307-37-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 135307-33-4 CAPLUS

CN 2-Oxazolamine, N,5-diphenyl- (9CI) (CA INDEX NAME)



RN 135307-37-8 CAPLUS

CN 2-Oxazolamine, 5-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

128.86

296.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-17.25

-17.25

STN INTERNATIONAL LOGOFF AT 09:01:16 ON 02 MAR 2006